https://wxpress.wuxiapptec.com/index.html https://wxpress.wuxiapptec.com/innovation.html https://wxpress.wuxiapptec.com/community.html https://wxpress.wuxiapptec.com/WuxiGlobalForum.html https://wxpress.wuxiapptec.com/WuXiHealthcareForum.html https://wxpress.wuxiapptec.com/RareDiseaseWebinarSeriesandConcert.html https://wxpress.wuxiapptec.com/search.html https://wxpress.wuxiapptec.com/bold.html https://wxpress.wuxiapptec.com/detail/1/wuxi-global-forum-2022 https://wxpress.wuxiapptec.com/detail/10/wuxi-healthcare-forum-2022 https://wxpress.wuxiapptec.com/detail/17/fragile-x-syndrome-innovative-approaches-to-finding-a-cure https://wxpress.wuxiapptec.com/detail/18/rising-to-the-challenge-healthy-aging-forum-2022 https://wxpress.wuxiapptec.com/detail/21/wuxi-global-forum-2021 https://wxpress.wuxiapptec.com/detail/28/wuxi-global-forum-2020 https://wxpress.wuxiapptec.com/detail/31/wuxi-healthcare-forum-2021 https://wxpress.wuxiapptec.com/detail/32/wuxi-healthcare-forum-2020-solving-tomorrow-s-health-challenges https://wxpress.wuxiapptec.com/detail/46/wuxi-global-forum-2019 https://wxpress.wuxiapptec.com/detail/50/wuxi-global-forum-2018 https://wxpress.wuxiapptec.com/detail/54/fragile-x-syndrome-in-pursuit-of-a-cure https://wxpress.wuxiapptec.com/detail/55/call9-raises-24m-to-advance-elder-care-and-reduce-healthcare-costs https://wxpress.wuxiapptec.com/detail/56/china-market-authorization-holder-system-summit-2017-recap https://wxpress.wuxiapptec.com/detail/57/wuxi-breaks-ground-on-new-cell-therapy-manufacturing-facility-in-philadelphia https://wxpress.wuxiapptec.com/detail/58/wuxi-receives-2013-lilly-global-supplier-award https://wxpress.wuxiapptec.com/detail/59/wuxi-global-forum-2013 https://wxpress.wuxiapptec.com/detail/63/wuxi-global-forum-2014 https://wxpress.wuxiapptec.com/detail/65/fda-granted-orphan-drug-designation-to-ana-conjugated-dactinomycin-nanoemulsion-for-the-treatment-of-ewing-s-sarcoma https://wxpress.wuxiapptec.com/detail/66/sta-signs-supply-agreement-with-tesaro https://wxpress.wuxiapptec.com/detail/67/partner-in-news-trutag-uses-edible-barcodes-in-fight-against-counterfeit-drug-trade https://wxpress.wuxiapptec.com/detail/68/u-s-fda-approves-otsuka-and-lundbeck-s-rexulti-brexpiprazole-as-adjunctive-treatment-for-adults-with-major-depressive-disorder-and-as-a-treatment-for-adults-with-schizophrenia https://wxpress.wuxiapptec.com/detail/69/novartis-new-heart-failure-medicine-lcz696-now-called-entresto-tm-approved-by-fda-to-reduce-risk-of-cardiovascular-death-and-heart-failure-hospitalization https://wxpress.wuxiapptec.com/detail/72/fda-approves-ibalizumab-manufactured-by-wuxi https://wxpress.wuxiapptec.com/detail/74/dyax-corp-receives-fda-breakthrough-therapy-designation-for-dx-2930-for-prevention-of-attacks-of-hereditary-angioedema https://wxpress.wuxiapptec.com/detail/76/marketing-authorization-holder-system-summit https://wxpress.wuxiapptec.com/detail/77/wuxi-begins-construction-of-new-r-d-and-cgmp-manufacturing-campus-in-changzhou https://wxpress.wuxiapptec.com/detail/78/wuxi-presents-the-2012-life-science-and-chemistry-awards https://wxpress.wuxiapptec.com/detail/79/iressa-approved-by-us-fda-for-first-line-treatment-of-patients-with-advanced-egfr-mutation-positive-non-small-cell-lung-cancer https://wxpress.wuxiapptec.com/detail/80/jardiance-reduced-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-and-peripheral-artery https://wxpress.wuxiapptec.com/detail/81/newron-receives-fda-orphan-drug-designation-for-sarizotan-for-the-treatment-of-rett-syndrome https://wxpress.wuxiapptec.com/detail/83/anisina-receives-orphan-drug-designation-from-fda-for-neuroblastoma https://wxpress.wuxiapptec.com/detail/84/wuxi-s-pharmaceutical-development-services-division-merges-with-sta https://wxpress.wuxiapptec.com/detail/85/c2n-and-abbvie-announce-fda-orphagn-drug-designation-of-c2n-8e12-for-the-treatment-of-progressive-supranuclear-palsy https://wxpress.wuxiapptec.com/detail/88/bristol-myers-squibb-receives-u-s-fda-breakthrough-therapy-designation-for-investigational-hiv-1-attachment-inhibitor-for-heavily-treatment-experienced-patients https://wxpress.wuxiapptec.com/detail/89/fda-approves-novartis-drug-odomzo-sonidegib-for-locally-advanced-basal-cell-carcinoma-a-form-of-skin-cancer https://wxpress.wuxiapptec.com/detail/90/fda-approves-technivie-for-treatment-of-chronic-hepatitis-c-genotype-4 https://wxpress.wuxiapptec.com/detail/91/construction-of-new-biosafety-testing-facility-in-suzhou-completed https://wxpress.wuxiapptec.com/detail/92/generation-bio-announces-100-million-series-b-financing-to-advance-genewave-platform-for-re-dosable-gene-therapy https://wxpress.wuxiapptec.com/detail/93/fda-approves-daklinza-daclatasvir-for-the-treatment-of-patients-with-chronic-hepatitis-c-genotype-3 https://wxpress.wuxiapptec.com/detail/96/sanofi-and-regeneron-announce-fda-approval-of-praluent-alirocumab-injection-the-first-pcsk9-inhibitor-in-the-u-s-for-the-treatment-of-high-ldl-cholesterol-in-adult-patients https://wxpress.wuxiapptec.com/detail/98/progenics-announces-breakthrough-therapy-designation-for-azedra-in-pheochromocytoma-and-paraganglioma https://wxpress.wuxiapptec.com/detail/99/osmotica-announces-its-osmolex-er-has-been-awarded-orphan-drug-status-by-the-united-states-fda https://wxpress.wuxiapptec.com/detail/100/webinar-breakthrough-drugs-the-story-behind-the-story https://wxpress.wuxiapptec.com/detail/101/wuxi-completes-construction-of-new-materials-characterization-facility-in-st-paul https://wxpress.wuxiapptec.com/detail/102/wuxi-s-toxicology-facility-in-suzhou-passes-oecd-glp-inspection https://wxpress.wuxiapptec.com/detail/103/amarantus-sees-manf-protein-discovery-as-a-path-to-new-effective-therapy-for-parkinson-s https://wxpress.wuxiapptec.com/detail/104/the-u-s-fda-completed-pre-license-inspection-pli-of-wuxi-biologics-cgmp-manufacturing-facilities-for-production-of-tmb-355-ibalizumab- https://wxpress.wuxiapptec.com/detail/105/targos-and-wuxi-collaborate-on-clinical-biomarker-services-and-pathology-training-in-china https://wxpress.wuxiapptec.com/detail/106/eisai-s-in-house-developed-novel-anticancer-agent-lenvima-receives-breakthrough-therapy-designation-from-u-s-fda-for-renal-cell-carcinoma https://wxpress.wuxiapptec.com/detail/107/inside-perspectives-numedii-banking-on-artificial-intelligence-to-expedite-the-discovery-of-effective-new-medicines https://wxpress.wuxiapptec.com/detail/108/inside-perspectives-exscientia-s-ceo-predicts-ai-will-up-the-ante-for-drug-hunters https://wxpress.wuxiapptec.com/detail/109/wuxi-and-omt-expand-human-antibody-development-and-commercial-opportunities https://wxpress.wuxiapptec.com/detail/110/wuxi-and-lilly-collaborate-to-develop-novel-therapeutics-in-china https://wxpress.wuxiapptec.com/detail/111/wuxi-begins-operation-of-new-high-potency-api-laboratory https://wxpress.wuxiapptec.com/detail/112/fda-approves-genentech-s-cotellic-cobimetinib-in-combination-with-zelboraf-vemurafenib-in-advanced-melanoma https://wxpress.wuxiapptec.com/detail/113/inside-perspectives-industry-pioneer-vijay-pande-lays-groundwork-for-applying-ai-to-medicine https://wxpress.wuxiapptec.com/detail/114/chinese-premier-li-keqiang-visits-wuxi-headquarters-in-shanghai https://wxpress.wuxiapptec.com/detail/115/vivace-therapeutics-banking-on-small-molecules-for-new-cancer-treatments https://wxpress.wuxiapptec.com/detail/116/teva-announces-breakthrough-therapy-designation-for-sd-809-granted-by-fda-for-the-treatment-of-tardive-dyskinesia https://wxpress.wuxiapptec.com/detail/117/strong-science-commitment-to-research-infrastructure-propel-german-biotech-growth https://wxpress.wuxiapptec.com/detail/119/u-s-fda-approves-gilead-s-single-tablet-regimen-genvoya-for-treatment-of-hiv-1-infection https://wxpress.wuxiapptec.com/detail/120/wuxi-s-webinar-on-breakthrough-drugs-draws-strong-attendance https://wxpress.wuxiapptec.com/detail/121/congratulations-to-novira-therapeutics-for-its-acquisition-agreement-with-johnson-johnson https://wxpress.wuxiapptec.com/detail/122/wuxi-manufacturing-subsidiary-sta-receives-quality-cmo-award https://wxpress.wuxiapptec.com/detail/123/imbruvica-and-its-impact-on-patients https://wxpress.wuxiapptec.com/detail/124/wuxi-receives-janssen-r-d-suppliers-award https://wxpress.wuxiapptec.com/detail/126/paratek-pharmaceuticals-receives-fda-fast-track-designation-for-omadacycline https://wxpress.wuxiapptec.com/detail/127/prothena-seeking-to-develop-therapies-to-block-underlying-cause-of-parkinson-s-disease https://wxpress.wuxiapptec.com/detail/129/wuxi-receives-merck-awards-for-achieving-team-milestones https://wxpress.wuxiapptec.com/detail/130/gw-hits-the-fda-fast-track-with-its-cannabis-based-epilepsy-drug-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/131/u-s-fda-approves-gsk-s-nucala-mepolizumab-to-treat-severe-asthma https://wxpress.wuxiapptec.com/detail/132/novira-s-novel-approach-to-anti-hbv-drug-discovery https://wxpress.wuxiapptec.com/detail/133/wuxipra-officially-starts-operations https://wxpress.wuxiapptec.com/detail/134/agilis-biotherapeutic-s-gene-therapy-receives-fda-orphan-drug-status-for-rare-genetic-disorder https://wxpress.wuxiapptec.com/detail/135/merck-receives-breakthrough-therapy-designation-from-u-s-fda-for-keytruda-in-advanced-colorectal-cancer https://wxpress.wuxiapptec.com/detail/136/wuxi-s-toxicology-facility-in-suzhou-passes-fda-inspection https://wxpress.wuxiapptec.com/detail/137/world-class-scientists-lecture-at-wuxi https://wxpress.wuxiapptec.com/detail/138/michael-j-fox-foundation-ceo-sees-significant-progress-in-treating-causes-of-parkinson-s-disease https://wxpress.wuxiapptec.com/detail/139/boehringer-bags-a-breakthrough-tag-for-its-pradaxa-antidote-source-fierce-biotech- https://wxpress.wuxiapptec.com/detail/140/fda-grants-breakthrough-therapy-designation-for-daiichi-sankyo-and-plexxikon-s-investigational-csf-1r-inhibitor-pexidartinib-in-tenosynovial-giant-cell-tumor https://wxpress.wuxiapptec.com/detail/141/canada-sees-biotech-as-key-asset-and-priority-for-its-economic-growth https://wxpress.wuxiapptec.com/detail/142/fda-approves-new-novartis-dual-combination-bronchodilator-utibron-neohaler-for-patients-with-chronic-obstructive-pulmonary-disease https://wxpress.wuxiapptec.com/detail/143/bms-receives-approval-from-the-u-s-fda-for-yervoy-ipilimumab-as-adjuvant-treatment-for-fully-resected-stage-iii-melanoma https://wxpress.wuxiapptec.com/detail/144/wuxi-celebrates-partnerships-innovation-during-bio-2017-cruise-around-san-diego-bay https://wxpress.wuxiapptec.com/detail/146/inside-perspectives-on-gene-editing-an-interview-with-cellectis-ceo-andr-choulika https://wxpress.wuxiapptec.com/detail/148/inside-perspectives-on-gene-editing-an-interview-with-genomics-pioneer-george-m-church-of-harvard-university https://wxpress.wuxiapptec.com/detail/149/inside-perspectives-gene-editing-takes-center-stage https://wxpress.wuxiapptec.com/detail/151/a-passion-for-precision-medicines-how-three-start-ups-are-changing-the-paradigm https://wxpress.wuxiapptec.com/detail/152/wuxi-apptec-expands-site-in-california-for-pharmaceutical-r-d-services https://wxpress.wuxiapptec.com/detail/153/wuxi-apptec-lists-h-shares-on-the-hong-kong-stock-exchange https://wxpress.wuxiapptec.com/detail/154/agex-therapeutics-aims-to-use-immortal-cells-to-boost-human-healthspan https://wxpress.wuxiapptec.com/detail/155/drug-hunter-discovering-new-frontiers-in-cancer-treatments-beyond https://wxpress.wuxiapptec.com/detail/156/improving-the-odds-in-cancer-with-first-time-immunotherapies https://wxpress.wuxiapptec.com/detail/157/fda-approves-imlygic-as-first-oncolytic-viral-therapy-in-the-u-s- https://wxpress.wuxiapptec.com/detail/158/u-s-fda-approves-belbuca-buprenorphine-buccal-film-for-chronic-pain-management https://wxpress.wuxiapptec.com/detail/159/understanding-and-slowing-the-human-aging-clock-paving-a-path-via-protein-stability https://wxpress.wuxiapptec.com/detail/160/fda-approves-alexion-pharma-s-metabolic-disorder-drug https://wxpress.wuxiapptec.com/detail/161/brave-science-putting-the-hutzpah-in-early-stage-drug-discovery https://wxpress.wuxiapptec.com/detail/162/wuxi-launches-medical-device-testing-services-in-china https://wxpress.wuxiapptec.com/detail/163/-every-client-is-a-partner-chinabio-interview https://wxpress.wuxiapptec.com/detail/164/fda-approves-j-j-s-chemotherapy-yondelis-for-certain-types-of-advanced-soft-tissue-sarcoma https://wxpress.wuxiapptec.com/detail/165/m3-biotechnology-charts-its-own-unique-course-in-the-fight-against-alzheimer-s https://wxpress.wuxiapptec.com/detail/166/fda-approves-merrimack-s-pancreatic-cancer-drug https://wxpress.wuxiapptec.com/detail/167/atara-bio-s-activin-inhibitor-for-ovarian-cancer-receives-fda-orphan-drug-designation https://wxpress.wuxiapptec.com/detail/168/pfizer-s-inotuzumab-ozogamicin-receives-fda-breakthrough-therapy-designation-for-acute-lymphoblastic-leukemia https://wxpress.wuxiapptec.com/detail/169/gut-instinct-leveraging-the-microbiome-and-human-immune-system-to-dramatically-transform-medicine https://wxpress.wuxiapptec.com/detail/170/dr-peter-schultz-ceo-of-the-scripps-research-institute-visits-wuxi-headquarters-in-shanghai https://wxpress.wuxiapptec.com/detail/171/6-dimensions-capital-closed-oversubscribed-1st-usd-fund-and-rmb-fund-bringing-total-aum-over-rmb-10bn-usd-1-5bn- https://wxpress.wuxiapptec.com/detail/173/global-leader-in-aging-research-pursues-multiple-strategies-in-quest-for-improving-health-span https://wxpress.wuxiapptec.com/detail/174/cognition-therapeutics-undaunted-warrior-in-the-battle-against-alzheimer-s https://wxpress.wuxiapptec.com/detail/175/wuxi-pharmatech-corporate-venture-fund-participates-in-syros-30m-series-a https://wxpress.wuxiapptec.com/detail/176/fda-approves-praxbind-the-first-reversal-agent-for-the-anticoagulant-pradaxa https://wxpress.wuxiapptec.com/detail/177/wuxi-receives-2015-asian-cro-company-of-the-year-award-from-frost-sullivan https://wxpress.wuxiapptec.com/detail/178/harnessing-science-for-the-most-neglected-diseases https://wxpress.wuxiapptec.com/detail/179/casi-pharmaceuticals-receives-eu-orphan-drug-designation-for-enmd-2076-to-treat-hepatocellular-carcinoma-including-fibrolamellar-carcinoma https://wxpress.wuxiapptec.com/detail/180/convergence-how-one-startup-is-taking-the-guesswork-out-of-drug-discovery-via-genomics https://wxpress.wuxiapptec.com/detail/181/wuxi-launches-mobile-oncowuxi-the-world-s-first-app-for-accessing-oncology-services https://wxpress.wuxiapptec.com/detail/182/rebiotix-receives-breakthrough-therapy-designation-for-rbx2660-a-microbiota-restoration-therapy-mrt-for-the-treatment-of-recurrent-clostridium-difficile-infection https://wxpress.wuxiapptec.com/detail/183/funding-crazy-ideas-building-extraordinary-companies https://wxpress.wuxiapptec.com/detail/184/solid-as-a-rock-creating-a-strong-foundation-for-developing-first-in-class-treatments-to-fight-aggressive-cancers https://wxpress.wuxiapptec.com/detail/185/bms-opdivo-nivolumab-receives-expanded-fda-approval-in-previously-treated-metastatic-non-small-cell-lung-cancer-nsclc-offering-improved-survival-to-more-patients https://wxpress.wuxiapptec.com/detail/186/maxcyte-driving-new-generation-of-cell-based-medicines https://wxpress.wuxiapptec.com/detail/187/inside-perspectives-numerate-aims-for-speedier-drug-development-with-artificial-intelligence https://wxpress.wuxiapptec.com/detail/188/lilly-receives-fda-breakthrough-therapy-designation-for-abemaciclib-a-cdk-4-and-6-inhibitor-in-advanced-breast-cancer https://wxpress.wuxiapptec.com/detail/189/deep-impact-how-passion-dedication-038-good-science-revived-a-life-saving-drug https://wxpress.wuxiapptec.com/detail/190/wuxi-webinar-demystifying-product-development-in-china-attracts-big-audience https://wxpress.wuxiapptec.com/detail/191/inhibikase-developing-revolutionary-therapy-to-reverse-the-course-of-parkinson-s-disease https://wxpress.wuxiapptec.com/detail/192/dr-james-pusey-named-president-and-general-manager-of-wuxipra https://wxpress.wuxiapptec.com/detail/193/wuxi-hosts-symposium-expediting-your-preclinical-development-timeline-with-an-integrated-cro https://wxpress.wuxiapptec.com/detail/194/aztherapies-targets-neuroinflammation-to-slowdown-or-halt-alzheimer-s-progression https://wxpress.wuxiapptec.com/detail/195/tarix-orphan-receives-fda-fast-track-designation-for-txa127-as-potential-treatment-for-duchenne-muscular-dystrophy https://wxpress.wuxiapptec.com/detail/196/-the-china-evolution-pharmasia-interview https://wxpress.wuxiapptec.com/detail/197/-shared-pathways-to-success-viela-bio-8217-s-quest-to-develop-first-in-class-molecules-to-treat-high-unmet-medical-needs https://wxpress.wuxiapptec.com/detail/198/wuxi-apptec-receives-2017-global-integrated-drug-r-d-services-competitive-strategy-innovation-leadership-award-from-frost-sullivan https://wxpress.wuxiapptec.com/detail/199/fda-approves-alkermes-s-schizophrenia-drug https://wxpress.wuxiapptec.com/detail/200/fda-approved-merck-s-drug-keytruda-for-lung-cancer-treatment https://wxpress.wuxiapptec.com/detail/201/agenebio-believes-a-switch-in-research-strategy-can-make-alzheimer-s-preventable https://wxpress.wuxiapptec.com/detail/202/webinar-break-the-cfda-code-summary-of-latest-changes-and-impacts-in-china-regulatory-policies https://wxpress.wuxiapptec.com/detail/203/wuxi-apptec-acquires-researchpoint-global-to-better-enable-clinical-development-worldwide https://wxpress.wuxiapptec.com/detail/204/fda-approval-brings-first-gene-therapy-to-the-united-states https://wxpress.wuxiapptec.com/detail/205/wuxi-hosts-symposium-strategies-for-developing-a-successful-global-clinical-and-commercial-api-supply-chain-cphi-2015 https://wxpress.wuxiapptec.com/detail/206/wuxi-svp-chris-chen-to-deliver-keynote-speech-at-ibc-s-bioprocess-international-china-conference https://wxpress.wuxiapptec.com/detail/207/merck-and-pfizer-announce-fda-orphan-drug-designation-for-investigational-immunotherapy-avelumab-in-merkel-cell-carcinoma https://wxpress.wuxiapptec.com/detail/208/drug-makers-developing-non-opioid-pain-alternatives-to-battle-the-opioid-epidemic https://wxpress.wuxiapptec.com/detail/209/wuxi-employees-honored-at-acs-national-meeting https://wxpress.wuxiapptec.com/detail/210/merck-kgaa-and-pfizer-collaborate-with-dako-an-agilent-technologies-company-on-development-of-companion-diagnostic-for-investigational-anti-pd-l1-antibody-avelumab https://wxpress.wuxiapptec.com/detail/211/-building-blocks-of-success-pushing-the-frontiers-of-medicine-to-prevent-disease https://wxpress.wuxiapptec.com/detail/212/taiho-oncology-inc-announces-fda-approval-of-lonsurf-for-refractory-metastatic-colorectal-cancer https://wxpress.wuxiapptec.com/detail/213/fiercebiotech-s-2013-fierce-15-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/215/bio-2018-going-deep-how-ai-and-machine-learning-will-transform-drug-discovery https://wxpress.wuxiapptec.com/detail/216/wuxi-sta-changzhou-site-passes-first-u-s-fda-inspection https://wxpress.wuxiapptec.com/detail/218/webinar-simplicity-by-design-continuous-direct-compression-manufacturing https://wxpress.wuxiapptec.com/detail/219/forging-the-unknown-frontiers-of-chemistry-and-science https://wxpress.wuxiapptec.com/detail/220/wuxi-apptec-announces-listing-of-initial-public-offering-of-common-stock-on-shanghai-stock-exchange https://wxpress.wuxiapptec.com/detail/222/congratulations-to-foundation-medicine-for-a-successful-ipo https://wxpress.wuxiapptec.com/detail/223/hydra-biosciences-sees-trp-ion-channels-as-pathway-to-opioid-alternatives https://wxpress.wuxiapptec.com/detail/224/meet-wuxi-s-israeli-partner-an-interview-with-ran-nussbaum-co-founder-and-managing-partner-of-pontifax https://wxpress.wuxiapptec.com/detail/225/wuxi-receives-2015-open-access-r-d-technology-leadership-award-from-frost-sullivan https://wxpress.wuxiapptec.com/detail/226/wuxi-cfo-edward-hu-to-discuss-vc-funding-at-bio-china https://wxpress.wuxiapptec.com/detail/227/fda-granted-orphan-drug-designation-to-spk-9001-for-the-treatment-of-hemophilia-b https://wxpress.wuxiapptec.com/detail/228/dimension-therapeutics-announces-fda-acceptance-of-investigational-new-drug-application-and-orphan-drug-designation-for-lead-candidate-dtx101-in-patients-with-hemophilia-b https://wxpress.wuxiapptec.com/detail/229/abbvie-s-humira-receives-first-and-only-u-s-food-and-drug-administration-approval-for-moderate-to-severe-hidradentis-suppurativa https://wxpress.wuxiapptec.com/detail/230/repositioning-existing-small-molecule-drugs-an-important-element-of-new-drug-discovery https://wxpress.wuxiapptec.com/detail/231/sanofi-ceo-remains-positive-on-china-and-other-emerging-markets-source-chinabio-today- https://wxpress.wuxiapptec.com/detail/232/fda-grants-genentech-s-alectinib-priority-review-for-specific-type-of-alk-positive-lung-cancer https://wxpress.wuxiapptec.com/detail/233/an-interview-with-dr-lawson-macartney-ceo-of-ambrx-pharmaceuticals https://wxpress.wuxiapptec.com/detail/234/wellstat-therapeutics-announces-fda-approval-of-xuriden-to-treat-rare-pediatric-disorder-hereditary-orotic-aciduria https://wxpress.wuxiapptec.com/detail/235/algomedix-hopes-new-class-of-pain-drugs-will-curb-dangers-of-opioids https://wxpress.wuxiapptec.com/detail/236/wuxi-global-forum-2015 https://wxpress.wuxiapptec.com/detail/237/rigel-granted-orphan-drug-designation-for-fostamatinib-in-itp https://wxpress.wuxiapptec.com/detail/238/wuxi-partners-with-qb3-on-its-new-incubator-in-san-francisco https://wxpress.wuxiapptec.com/detail/239/wuxi-apptec-expands-site-in-the-united-states-for-drug-development-testing-services https://wxpress.wuxiapptec.com/detail/240/u-s-fda-grants-breakthrough-therapy-designation-for-genentech-s-investigational-medicine-ace910-for-people-with-hemophilia-a-with-factor-viii-inhibitors https://wxpress.wuxiapptec.com/detail/241/inside-perspectives-on-the-discovery-of-the-hep-c-combo-therapy-elbasvir-grazoprevir https://wxpress.wuxiapptec.com/detail/242/wuxi-svp-rich-soll-to-provide-perspectives-on-oursourcing-at-china-forum https://wxpress.wuxiapptec.com/detail/243/loxo-oncology-announces-fda-orphan-drug-designation-granted-to-loxo-101-for-treatment-of-soft-tissue-sarcoma https://wxpress.wuxiapptec.com/detail/244/hutchison-medipharma-out-licenses-cancer-drug-to-lilly-for-86-5-million-source-hutchinson-medipharma- https://wxpress.wuxiapptec.com/detail/245/nutra-pharma-receives-orphan-drug-designation-from-us-fda-for-treatment-of-multiple-sclerosis-in-children https://wxpress.wuxiapptec.com/detail/246/top-10-drugmakers-in-emerging-markets-source-fiercepharma- https://wxpress.wuxiapptec.com/detail/247/platform-for-success-gossamer-bio-s-quest-to-build-a-sustainable-company-038-culture https://wxpress.wuxiapptec.com/detail/248/fda-approves-amgen-s-new-cholesterol-lowering-medication-repatha-evolocumab- https://wxpress.wuxiapptec.com/detail/250/wuxi-s-sta-subsidiary-receives-first-approval-from-japanese-regulatory-authorities https://wxpress.wuxiapptec.com/detail/253/early-stage-an-inside-look-at-how-personal-experience-translates-into-next-generation-biotechs-treatments-for-patients https://wxpress.wuxiapptec.com/detail/254/wuxi-to-be-exclusive-supplier-of-laboratory-testing-services-to-lee-s-pharm https://wxpress.wuxiapptec.com/detail/255/the-first-wuxi-healthcare-forum-opens-in-shanghai https://wxpress.wuxiapptec.com/detail/256/biocancell-receives-fda-fast-track-designation https://wxpress.wuxiapptec.com/detail/257/a-conversation-with-carl-firth-ceo-of-aslan-pharmaceuticals https://wxpress.wuxiapptec.com/detail/259/ability-pharmaceuticals-receives-orphan-drug-designation-from-u-s-fda-for-abtl0812-for-treatment-of-neuroblastoma https://wxpress.wuxiapptec.com/detail/260/expediting-development-of-biologics-in-china-from-strategy-to-regulatory-expectations-and-beyond https://wxpress.wuxiapptec.com/detail/261/fda-grants-orphan-drug-designation-for-tocagen-s-toca-511-toca-fc-an-investigational-immuno-oncology-treatment-for-glioblastoma https://wxpress.wuxiapptec.com/detail/262/wuxi-sta-announces-to-build-a-new-r-038-d-center-in-shanghai https://wxpress.wuxiapptec.com/detail/263/fda-grants-breakthrough-therapy-designation-to-exelixis-cabozantinib-for-the-treatment-of-renal-cell-carcinoma-in-patients-who-received-one-prior-therapy https://wxpress.wuxiapptec.com/detail/265/fda-expands-use-of-novartis-drug-promacta-to-include-treatment-of-children-ages-1-and-older-with-chronic-immune-thrombocytopenia https://wxpress.wuxiapptec.com/detail/266/top-biopharma-executive-jeremy-levin-leads-bio-s-efforts-to-battle-opioid-crisis https://wxpress.wuxiapptec.com/detail/267/new-approaches-to-rekindle-innovation https://wxpress.wuxiapptec.com/detail/268/biologics-grab-all-the-headlines-but-small-molecules-still-at-forefront https://wxpress.wuxiapptec.com/detail/269/wuxi-global-forum-2016 https://wxpress.wuxiapptec.com/detail/270/inside-perspectives-on-cancer-immunotherapy-an-interview-with-kineta-s-shawn-iadonato https://wxpress.wuxiapptec.com/detail/271/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection-source-merck- https://wxpress.wuxiapptec.com/detail/272/wuxi-apptec-testing-facilities-complete-three-regulatory-inspections-from-us-fda-oecd-and-cnas-with-excellent-results https://wxpress.wuxiapptec.com/detail/273/wuxi-night-boston-acs-2015 https://wxpress.wuxiapptec.com/detail/275/sarepta-therapeutics-receives-rare-pediatric-disease-designation-from-fda-for-eteplirsen-for-the-potential-treatment-of-duchenne-muscular-dystrophy https://wxpress.wuxiapptec.com/detail/276/kineta-developing-non-opioid-pain-drug-that-does-more-than-just-mask-the-problem https://wxpress.wuxiapptec.com/detail/277/what-does-the-fda-inspection-mean-to-sta-and-its-customers- https://wxpress.wuxiapptec.com/detail/278/the-top-10-biotech-ipos-of-2013-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/279/seres-therapeutics-inc-announces-fda-orphan-drug-designation-for-ser-109-for-the-prevention-of-recurrent-clostridium-difficile-infection-in-adults https://wxpress.wuxiapptec.com/detail/280/mtg-biotherapeutics-announces-that-mtg-201-was-granted-orphan-drug-designation-by-the-us-fda-for-the-treatment-of-malignant-mesothelioma https://wxpress.wuxiapptec.com/detail/281/inside-perspectives-on-cancer-immunotherapy-an-interview-with-tcr-sup-2-sup-therapeutics-ceo-garry-menzel https://wxpress.wuxiapptec.com/detail/282/experienced-investment-analyst-predicts-non-opioid-pain-drugs-will-reduce-opioid-abuse-and-health-care-costs https://wxpress.wuxiapptec.com/detail/283/first-chinese-made-biologics-slated-for-human-trials-in-the-west-source-nature-medicine- https://wxpress.wuxiapptec.com/detail/284/biomarin-receives-rare-pediatric-disease-designation-from-fda-for-drisapersen-for-the-potential-treatment-of-duchenne-muscular-dystrophy https://wxpress.wuxiapptec.com/detail/285/la-jolla-pharmaceutical-company-receives-orphan-drug-designation-for-two-novel-compounds-for-fibrodysplasia-ossificans-progressiva https://wxpress.wuxiapptec.com/detail/286/bring-out-the-confetti-7-of-2013-s-launches-will-join-sovaldi-tecfidera-in-blockbuster-land-source-fierce-biotech- https://wxpress.wuxiapptec.com/detail/287/sprout-pharmaceuticals-receives-fda-approval-of-addyi- https://wxpress.wuxiapptec.com/detail/288/inside-perspectives-on-cancer-immunotherapy-an-interview-with-juno-ceo-hans-bishop https://wxpress.wuxiapptec.com/detail/289/angling-for-early-ok-amgen-wins-breakthrough-title-for-leukemia-drug-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/290/fda-granted-orphan-drug-designation-to-celgene-s-ged-0301-for-treatment-of-pediatric-crohn-s-disease https://wxpress.wuxiapptec.com/detail/291/wuxi-manufacturing-facility-passes-fda-inspection https://wxpress.wuxiapptec.com/detail/292/wuxi-and-trutag-technology-advances-edible-on-dose-authentication-solution-for-pharmaceuticals https://wxpress.wuxiapptec.com/detail/293/wuxi-successfully-completes-its-first-2000l-disposable-bioreactor-run-using-an-ns0-cell-line https://wxpress.wuxiapptec.com/detail/294/-wuxi-s-mission-critical-fostering-innovation-by-servicing-biopharma-an-interview-by-bioworld https://wxpress.wuxiapptec.com/detail/295/wuxi-oncology-receives-award-for-most-valuable-team-player-from-genentech https://wxpress.wuxiapptec.com/detail/296/aslan-pharmaceuticals-varlitinib-receives-orphan-drug-designation-for-treatment-of-cholangiocarcinoma https://wxpress.wuxiapptec.com/detail/297/insys-therapeutics-receives-fda-orphan-drug-designation-for-its-pharmaceutical-cannabidiol-for-the-treatment-of-infantile-spasms https://wxpress.wuxiapptec.com/detail/298/wuxi-teams-with-mayo-clinic-s-center-for-individualized-medicine-to-support-personalized-medicine-discovery https://wxpress.wuxiapptec.com/detail/299/novartis-leading-car-t-cancer-therapy-gains-breakthrough-status-at-the-fda-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/300/u-s-fda-granted-orphan-drug-designation-to-inecalcitol-for-treatment-of-acute-myeloid-leukemia https://wxpress.wuxiapptec.com/detail/301/beigene-out-licenses-second-molecule-to-merck-serono-in-232-million-deal-source-chinabio-today- https://wxpress.wuxiapptec.com/detail/302/inside-perspectives-on-cancer-immunotherapy-an-interview-with-mpm-s-christiana-bardon https://wxpress.wuxiapptec.com/detail/303/hua-medicine-breaking-new-ground https://wxpress.wuxiapptec.com/detail/304/wuxi-global-forum-2017 https://wxpress.wuxiapptec.com/detail/305/dr-steve-yang-interview-a-returnee-s-perspective https://wxpress.wuxiapptec.com/detail/306/wuxi-partners-with-pharmacyclics https://wxpress.wuxiapptec.com/detail/308/boehringer-s-lung-drug-wins-fda-breakthrough-tag-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/309/fda-approves-the-first-3d-printed-drug-product https://wxpress.wuxiapptec.com/detail/310/early-stage-tie-ups-surge-as-biotech-bankrollers-spend-big-on-phi-source-fierce-biotech- https://wxpress.wuxiapptec.com/detail/311/finacea-azelaic-acid-foam-15-approved-by-u-s-fda-for-topical-treatment-of-the-inflammatory-papules-and-pustules-of-mild-to-moderate-rosacea https://wxpress.wuxiapptec.com/detail/312/intermune-grabs-fda-breakthough-therapy-designation-for-ipf-drug-pirfenidone-source-biospace- https://wxpress.wuxiapptec.com/detail/313/gsk-builds-academic-partnership-in-epigenetic-drug-discovery-source-drugdiscovery-development- https://wxpress.wuxiapptec.com/detail/314/goldenbiotech-s-new-drug-ghhcc-was-granted-orphan-drug-designation-for-hepatocellular-carcinoma-by-fda https://wxpress.wuxiapptec.com/detail/316/emd-serono-creates-spin-off-company-for-infertility-treatment-source-drugdiscovery-development- https://wxpress.wuxiapptec.com/detail/317/bio-2017-disease-focused-foundations-an-increasing-influence-in-drug-discovery-and-development https://wxpress.wuxiapptec.com/detail/318/sanofi-touts-promising-phiii-data-on-next-gen-diabetes-therapy-as-rivals-circle-source-fierce-biotech- https://wxpress.wuxiapptec.com/detail/319/an-interview-with-dr-paul-liu-vice-president-and-head-of-biosafety-testing-services-in-suzhou-china https://wxpress.wuxiapptec.com/detail/320/an-interview-with-the-new-head-of-idsu-dr-steve-yang-executive-vice-president-and-chief-operating-officer-of-wuxi-apptec https://wxpress.wuxiapptec.com/detail/321/celgene-commits-3-3b-in-whopper-cancer-stem-cell-deal-with-oncomed-source-fierce-biotech- https://wxpress.wuxiapptec.com/detail/322/celgene-s-bold-approach-to-creating-next-generation-therapeutics https://wxpress.wuxiapptec.com/detail/323/roche-enters-cancer-treatment-alliance-with-molecular-partners-source-drugdiscovery-development- https://wxpress.wuxiapptec.com/detail/324/wuxi-presents-2013-life-science-and-chemistry-awards https://wxpress.wuxiapptec.com/detail/325/idea-factory-from-the-classroom-to-the-lab-robert-langer-s-impact-is-felt-around-the-globe https://wxpress.wuxiapptec.com/detail/326/j-j-partner-aduro-grabs-an-fda-breakthrough-nod-for-its-immuno-oncology-combo-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/327/lucky-2013-the-biotech-year-in-review-source-biospace- https://wxpress.wuxiapptec.com/detail/328/pfizer-s-r-d-chief-on-how-drug-research-is-evolving-source-forbes- https://wxpress.wuxiapptec.com/detail/329/the-5-biggest-trends-in-biopharma-r-d-in-2013-source-fierce-biotech- https://wxpress.wuxiapptec.com/detail/331/2013-s-biggest-medical-breakthroughs-from-mind-controlled-robotic-legs-to-hiv-vaccines-source-medical-daily- https://wxpress.wuxiapptec.com/detail/332/winners-of-wuxi-pharmatech-awards-inducted-into-prestigious-academies https://wxpress.wuxiapptec.com/detail/333/team-wuxi-at-shanghai-international-marathon https://wxpress.wuxiapptec.com/detail/334/wuxi-at-chemoutsourcing-2015 https://wxpress.wuxiapptec.com/detail/335/grading-pharma-in-2013-16-drug-companies-ranked-source-forbes- https://wxpress.wuxiapptec.com/detail/336/harnessing-the-collaborative-biopharma-ecosystem-to-drive-sector-wide-innovation https://wxpress.wuxiapptec.com/detail/337/wuxi-global-2017-forum-recap https://wxpress.wuxiapptec.com/detail/338/final-count-for-pharma-r-d-in-2013-gilead-s-sovaldi-among-27-new-drugs-approved-by-the-fda-source-medivo- https://wxpress.wuxiapptec.com/detail/339/gilead-sciences-and-wuxi-partner-for-a-dedicated-analytical-and-stability-testing-facility https://wxpress.wuxiapptec.com/detail/340/the-fda-approvals-of-2013-a-watershed-source-forbes- https://wxpress.wuxiapptec.com/detail/341/2014-global-life-sciences-outlook-source-deloitte- https://wxpress.wuxiapptec.com/detail/342/biologics-production-rapid-protein-expression-and-mammalian-cell-line-development https://wxpress.wuxiapptec.com/detail/343/6-u-s-institutions-receive-540m-in-cancer-research-funds-source-fiercebiotechresearch- https://wxpress.wuxiapptec.com/detail/344/wuxi-corporate-venture-fund-invests-in-innovative-cancer-imaging-business https://wxpress.wuxiapptec.com/detail/345/educational-seminar-series-navigating-the-preclinical-environment-for-cell-gene-therapies https://wxpress.wuxiapptec.com/detail/346/biopharma-s-middle-class-spent-big-in-2013-but-price-tags-are-on-the-rise-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/348/tsunami-of-biotech-ipos-will-test-investors-appetite-for-r-d-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/349/wuxi-facility-passes-us-fda-inspection-for-manufacture-of-api https://wxpress.wuxiapptec.com/detail/350/pulse-of-j-p-morgan-2014-interviews-with-17-biopharma-execs-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/351/wuxi-corporate-venture-fund-participates-in-aldea-pharmaceuticals-24m-series-b-financing https://wxpress.wuxiapptec.com/detail/352/annual-venture-investment-dollars-rise-7-and-exceed-2012-totals-according-to-the-moneytree-report-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/353/wuxi-selected-as-top-20-most-competitive-companies-in-chinese-pharmaceutical-industry https://wxpress.wuxiapptec.com/detail/357/wuxi-executive-luncheon-at-mixiii-biomed-2017 https://wxpress.wuxiapptec.com/detail/359/creating-a-new-legacy-a-look-inside-takeda-s-r-d-transformation https://wxpress.wuxiapptec.com/detail/360/the-biocentury-china-healthcare-summit-the-bridge-to-innovation https://wxpress.wuxiapptec.com/detail/361/wuxi-successfully-hosts-2nd-annual-wuxi-global-forum-a-video-summary https://wxpress.wuxiapptec.com/detail/362/the-top-drug-delivery-partnerships-of-2013-source-fiercedrugdelivery- https://wxpress.wuxiapptec.com/detail/363/ipo-boom-8-biotechs-bag-half-a-billion-in-a-banner-week-source-fiercebiotech- https://wxpress.wuxiapptec.com/detail/364/9-us-ipos-planned-for-the-week-of-feb-10-source-renaissancecapital- https://wxpress.wuxiapptec.com/detail/365/wuxi-apptec-group-and-mayo-clinic-form-joint-venture-to-deliver-clinical-diagnostic-services https://wxpress.wuxiapptec.com/detail/366/cell-therapy-webinar-series-developing-a-commercially-viable-process-for-cell-therapy-manufacture https://wxpress.wuxiapptec.com/detail/367/bayer-buys-dihon-to-add-traditional-chinese-medicine https://wxpress.wuxiapptec.com/detail/368/life-science-leaders-celebrate-global-partnerships-during-wuxi-global-forum-2018 https://wxpress.wuxiapptec.com/detail/369/webinar-a-new-resurgence-of-neuroscience-r-d https://wxpress.wuxiapptec.com/detail/370/wuxi-expands-in-u-s-with-acquisition-of-xenobiotic-laboratories-inc- https://wxpress.wuxiapptec.com/detail/372/wuxi-partners-with-pacific-biomarkers https://wxpress.wuxiapptec.com/detail/373/episode-i-tackling-alzheimer-s-disease-with-scale-system-speed https://wxpress.wuxiapptec.com/detail/374/ind-application-for-wuxi-medimmune-s-monoclonal-antibody-accepted-for-review-by-cfda https://wxpress.wuxiapptec.com/detail/375/foundation-medicine-and-wuxi-collaborate-to-offer-best-in-class-comprehensive-genomic-profiling-in-china https://wxpress.wuxiapptec.com/detail/376/china-announces-new-3-2-billion-drug-development-program-source-china-bio- https://wxpress.wuxiapptec.com/detail/377/fine-tuning-viral-clearance-approaches-enhancing-robust-steps-defining-the-limits https://wxpress.wuxiapptec.com/detail/378/wuxi-webinar-on-neuroscience-r-d-drew-over-400-registrations https://wxpress.wuxiapptec.com/detail/379/wuxi-corporate-venture-fund-invests-in-trutag-security-platform-for-drug-safety https://wxpress.wuxiapptec.com/detail/380/episode-ii-building-paths-towards-healthy-aging-through-innovation-an-industry-perspective https://wxpress.wuxiapptec.com/detail/381/congratulations-to-taimed-biologics-on-receiving-orphan-drug-designation-for-ibalizumab-from-fda https://wxpress.wuxiapptec.com/detail/382/china-takes-first-place-as-asia-s-leading-biopharma-cluster https://wxpress.wuxiapptec.com/detail/383/wuxi-discovery-biology-receives-excellent-partner-award- https://wxpress.wuxiapptec.com/detail/385/immutep-and-eddingpharm-start-production-of-immufact-imp321-at-wuxi https://wxpress.wuxiapptec.com/detail/387/china-to-remove-price-limits-on-some-essential-drugs-source-chinabio- https://wxpress.wuxiapptec.com/detail/388/webinar-the-unique-challenges-and-opportunities-in-rare-disease-r-d https://wxpress.wuxiapptec.com/detail/389/chinabio-helps-western-companies-come-to-china https://wxpress.wuxiapptec.com/detail/390/advancing-global-innovation-to-benefit-patients-in-china-and-around-the-world https://wxpress.wuxiapptec.com/detail/391/fighting-counterfeit-medicines-with-trutag-technologies https://wxpress.wuxiapptec.com/detail/392/emergent-biosolutions-receives-fda-approval-of-anthrasil-its-anthrax-immune-globulin-for-use-in-the-treatment-of-inhalational-anthrax https://wxpress.wuxiapptec.com/detail/394/chinabio-partnering-forum-20 https://wxpress.wuxiapptec.com/detail/395/episode-iii-the-future-of-aging-challenges-opportunities https://wxpress.wuxiapptec.com/detail/396/aduro-receives-orphan-drug-designation-for-crs-207-in-mesothelioma https://wxpress.wuxiapptec.com/detail/397/moving-the-needle-on-als-neuromuscular-disorders https://wxpress.wuxiapptec.com/detail/398/to-next-level-with-ai-driven-synthesis https://wxpress.wuxiapptec.com/detail/399/wuxi-global-webinar-accelerating-innovation-in-a-collaborative-biopharma-ecosystem- https://wxpress.wuxiapptec.com/detail/401/let-science-lead-a-special-online-forum-on-covid-19 https://wxpress.wuxiapptec.com/detail/402/wuxi-global-webinar-demystifying-product-development-in-china- https://wxpress.wuxiapptec.com/detail/403/wuxi-apptec-completes-acquisition-of-hd-biosciences https://wxpress.wuxiapptec.com/detail/404/acceleration-a-proven-approach-to-creating-vibrant-biotech-startup-ecosystems https://wxpress.wuxiapptec.com/detail/405/episode-iv-how-research-education-can-impact-an-aging-society-a-singapore-perspective https://wxpress.wuxiapptec.com/detail/406/rare-disease-neurofibromatosis https://wxpress.wuxiapptec.com/detail/407/dmd-charting-the-path-for-new-therapeutics-and-better-care https://wxpress.wuxiapptec.com/detail/408/winning-the-war-on-huntington-s-disease https://wxpress.wuxiapptec.com/detail/409/progress-in-halting-pompe-disease https://wxpress.wuxiapptec.com/detail/410/advances-in-rare-diseases-hemophilia https://wxpress.wuxiapptec.com/detail/411/wuxi-rare-disease-awareness-concert-2021 https://wxpress.wuxiapptec.com/detail/412/rare-disease-spinal-muscular-atrophy https://wxpress.wuxiapptec.com/detail/414/emerging-opportunities-in-multiple-sclerosis-and-neurosciences https://wxpress.wuxiapptec.com/detail/415/wuxi-apptec-recognized-by-frost-sullivan-with-2020-global-customer-value-leadership-award https://wxpress.wuxiapptec.com/detail/418/galderma-announces-fda-approval-of-full-prescription-strength-differin-gel-for-over-the-counter-acne-use https://wxpress.wuxiapptec.com/detail/419/fda-approves-shire-s-dry-eye-treatment https://wxpress.wuxiapptec.com/detail/420/the-new-healthcare-ecosystem-wuxi-healthcare-forum https://wxpress.wuxiapptec.com/detail/421/biotech-cmc-outsourcing-strategies-boston https://wxpress.wuxiapptec.com/detail/422/fda-approves-abbott-s-tecnis-symfony-lens-for-cataracts https://wxpress.wuxiapptec.com/detail/423/wuxi-s-sta-subsidiary-opens-operations-in-san-diego https://wxpress.wuxiapptec.com/detail/424/wuxi-s-sta-subsidiary-passed-third-u-s-fda-inspection https://wxpress.wuxiapptec.com/detail/426/wuxi-healthcare-forum-2019-meeting-tomorrow-s-health-challenges https://wxpress.wuxiapptec.com/detail/427/metabomed-a-new-venture-in-israel-s-start-up-ecosystem-that-tackles-cancer-s-altered-metabolism https://wxpress.wuxiapptec.com/detail/429/wuxi-sta-s-new-drug-product-manufacturing-facility-passes-first-european-mpa-gmp-inspection https://wxpress.wuxiapptec.com/detail/430/wuxi-s-partnership-with-eli-lilly-to-bring-novel-cardiovascular-medicines-to-china-named-finalist-in-scrip-awards https://wxpress.wuxiapptec.com/detail/431/wuxi-apptec-appoints-dr-frederick-h-hausheer-as-chief-medical-officer https://wxpress.wuxiapptec.com/detail/432/inside-perspectives-on-european-biotech-venture-investment-an-interview-with-forbion-capital-s-sander-slootweg https://wxpress.wuxiapptec.com/detail/433/wuxi-biologics-completes-construction-of-asia-s-largest-perfusion-biologics-manufacturing-facility-using-disposable-bioreactors https://wxpress.wuxiapptec.com/detail/434/wuxi-apptec-unveils-manufacturing-center-for-cutting-edge-cell-and-gene-therapies https://wxpress.wuxiapptec.com/detail/435/wuxi-apptec-announces-strong-first-quarter-2019-results https://wxpress.wuxiapptec.com/detail/436/a-personal-journey-in-creating-breakthrough-treatments-for-disease https://wxpress.wuxiapptec.com/detail/437/wuxi-apptec-acquires-pharmapace-to-enhance-biometrics-services-for-clinical-development https://wxpress.wuxiapptec.com/detail/438/wuxi-s-sta-leaders-provide-industry-trends-and-insights-during-cphi-worldwide-2016 https://wxpress.wuxiapptec.com/detail/439/fda-grants-accelerated-approval-to-new-treatment-for-advanced-soft-tissue-sarcoma https://wxpress.wuxiapptec.com/detail/440/fda-awards-21-grants-to-stimulate-product-development-for-rare-diseases https://wxpress.wuxiapptec.com/detail/441/novartis-announces-fda-approval-for-jadenutm-to-simplify-treatment-administration-for-patients-with-chronic-iron-overload https://wxpress.wuxiapptec.com/detail/442/wuxi-s-sta-biotech-cmc-outsourcing-boston-symposium-recap https://wxpress.wuxiapptec.com/detail/443/the-game-changing-potential-of-targeting-rna-with-small-molecules-more-than-turning-the-undruggable-to-druggable https://wxpress.wuxiapptec.com/detail/444/wuxi-apptec-receives-inaugural-company-of-the-year-award-from-bayhelix https://wxpress.wuxiapptec.com/detail/445/fda-approves-new-device-for-prevention-of-recurrent-strokes-in-certain-patients https://wxpress.wuxiapptec.com/detail/446/the-fight-against-acute-microbial-resistance-amr-goes-virtual-acurx-developing-antimicrobials-with-novel-biochemical-mechanism https://wxpress.wuxiapptec.com/detail/447/fda-research-to-help-speed-development-of-zika-virus-vaccines-and-therapeutics https://wxpress.wuxiapptec.com/detail/448/fda-approves-intrarosa-for-postmenopausal-women-experiencing-pain-during-sex https://wxpress.wuxiapptec.com/detail/449/fda-grants-amgen-priority-review-for-kyprolis-carfilzomib-supplemental-new-drug-application-for-the-treatment-of-relapsed-multiple-myeloma https://wxpress.wuxiapptec.com/detail/450/fda-approves-jardiance-to-reduce-cardiovascular-death-in-adults-with-type-2-diabetes https://wxpress.wuxiapptec.com/detail/451/fda-takes-steps-to-improve-hearing-aid-accessibility https://wxpress.wuxiapptec.com/detail/452/teva-announces-fda-approval-of-proair-respiclick https://wxpress.wuxiapptec.com/detail/453/fda-grants-accelerated-approval-to-new-treatment-for-advanced-ovarian-cancer https://wxpress.wuxiapptec.com/detail/454/storm-therapeutics-pioneering-new-rna-pathways-to-novel-therapies https://wxpress.wuxiapptec.com/detail/455/fda-expands-indication-for-continuous-glucose-monitoring-system-first-to-replace-fingerstick-testing-for-diabetes-treatment-decisions https://wxpress.wuxiapptec.com/detail/456/idera-announces-fda-orphan-drug-designation-for-imo-8400-for-the-treatment-of-diffuse-large-b-cell-lymphoma https://wxpress.wuxiapptec.com/detail/457/fda-approves-first-drug-for-spinal-muscular-atrophy https://wxpress.wuxiapptec.com/detail/458/curis-announces-orphan-drug-designation-for-cudc-907-in-diffuse-large-b-cell-lymphoma https://wxpress.wuxiapptec.com/detail/459/ascentage-pharma-announces-series-b-financing-of-rmb-500-million-to-advance-its-apoptosis-targeted-novel-therapeutics https://wxpress.wuxiapptec.com/detail/460/clovis-oncology-receives-breakthrough-therapy-designation-for-rucaparib-for-monotherapy-treatment-of-advanced-ovarian-cancer-in-patients-with-brca-mutated-tumors https://wxpress.wuxiapptec.com/detail/461/beijing-mabworks-company-completes-39-million-series-b-funding https://wxpress.wuxiapptec.com/detail/463/nobel-prize-laureate-professor-barry-sharpless-visits-wuxi https://wxpress.wuxiapptec.com/detail/464/grazoprevir-elbasvir-merck-s-investigational-chronic-hepatitis-c-therapy-granted-fda-breakthrough-therapy-designations https://wxpress.wuxiapptec.com/detail/465/prolong-pharmaceuticals-flagship-product-sanguinate-granted-orphan-drug-designation-by-the-fda https://wxpress.wuxiapptec.com/detail/466/fda-grants-bayer-bay-priority-review-for-stivarga-regorafenib-for-the-second-line-systemic-treatment-of-liver-cancer https://wxpress.wuxiapptec.com/detail/467/dbv-technologies-receives-fda-breakthrough-therapy-designation-for-viaskin-peanut-for-the-treatment-of-peanut-allergy-in-children https://wxpress.wuxiapptec.com/detail/468/sun-pharma-sunpharma-ns-announces-positive-topline-results-of-confirmatory-phase-3-clinical-trial-for-seciera-for-treatment-of-dry-eye https://wxpress.wuxiapptec.com/detail/469/neurotrope-receives-fda-orphan-drug-designation-for-bryostatin-in-the-treatment-of-fragile-x-syndrome https://wxpress.wuxiapptec.com/detail/470/nascent-biotech-announces-orphan-drug-designation-for-brain-cancer https://wxpress.wuxiapptec.com/detail/471/adamas-pharmaceuticals-receives-orphan-drug-designation-for-ads-5102-for-the-treatment-of-levodopa-induced-dyskinesia-associated-with-parkinson-s-disease https://wxpress.wuxiapptec.com/detail/472/apatone-received-odd-for-the-treatment-of-noninfected-painful-total-joint-without-mechanical-complication https://wxpress.wuxiapptec.com/detail/473/insitro-s-daphne-koller-discusses-machine-learning-predictive-biology-and-therapeutic-approaches-for-nonalcoholic-steatohepatitis-nash- https://wxpress.wuxiapptec.com/detail/474/reata-pharmaceuticals-bardoxolone-methyl-receives-fda-orphan-drug-designation-in-pulmonary-arterial-hypertension https://wxpress.wuxiapptec.com/detail/475/selective-mtorc1-modulation-as-novel-approaches-to-treating-diabetes-cancer-fibrosis-depression-and-beyond-distinct-from-rapamycin https://wxpress.wuxiapptec.com/detail/476/fda-approves-corlanor-ivabradine-to-reduce-the-risk-of-hospitalization-for-worsening-heart-failure-in-patients-with-chronic-heart-failure https://wxpress.wuxiapptec.com/detail/477/tremelimumab-granted-orphan-drug-designation-by-us-fda-for-treatment-of-malignant-mesothelioma https://wxpress.wuxiapptec.com/detail/478/fda-grants-odd-for-selumetinib-azd6244-for-the-treatment-of-uveal-melanoma https://wxpress.wuxiapptec.com/detail/479/interna-boldly-exploring-new-rna-technologies-to-tackle-cancer https://wxpress.wuxiapptec.com/detail/480/ultragenyx-granted-orphan-drug-designation-for-triheptanoin-for-the-treatment-of-glucose-transporter-type-1-deficiency-syndrome https://wxpress.wuxiapptec.com/detail/481/gazyva-obinutuzumab-granted-orphan-drug-designation-by-fda-for-treatment-of-follicular-lymphoma https://wxpress.wuxiapptec.com/detail/482/fda-grants-odd-for-reolysin-pelareorep-for-treatment-of-malignant-glioma https://wxpress.wuxiapptec.com/detail/483/samcyprone-obtained-odd-from-fda-for-treatment-of-malignant-melanoma-stage-iib-to-iv https://wxpress.wuxiapptec.com/detail/484/ang1005-granted-odd-for-treatment-of-breast-cancer-patients-with-brain-metastases https://wxpress.wuxiapptec.com/detail/485/mbx-8025-obtained-another-odd-for-treatment-of-patients-with-frederickson-type-i-or-v-hyperlipoproteinemia https://wxpress.wuxiapptec.com/detail/486/pfizer-receives-u-s-fda-breakthrough-therapy-designation-for-xalkori-crizotinib-for-the-treatment-of-patients-with-ros1-positive-non-small-cell-lung-cancer https://wxpress.wuxiapptec.com/detail/487/solaranrx-s-srx-1177-receives-fda-orphan-drug-designation-as-malignant-melanoma-treatment https://wxpress.wuxiapptec.com/detail/488/cantrixil-receives-orphan-drug-designation-from-fda https://wxpress.wuxiapptec.com/detail/489/capricor-granted-fda-orphan-drug-designation-for-allogeneic-cardiosphere-derived-cells-for-the-treatment-of-duchenne-muscular-dystrophy https://wxpress.wuxiapptec.com/detail/490/atyr-pharma-receives-orphan-drug-designation-for-resolaris-in-fshd https://wxpress.wuxiapptec.com/detail/491/thar-pharmaceuticals-received-orphan-drug-designation-for-its-zlm-for-treatment-of-complex-regional-pain-syndrome https://wxpress.wuxiapptec.com/detail/492/fda-grants-orphan-drug-designation-for-dcr-ph1-dicerna-s-investigational-therapy-for-the-treatment-of-primary-hyperoxaluria-type-1-ph1- https://wxpress.wuxiapptec.com/detail/493/gw-pharmaceuticals-receives-orphan-drug-designation-from-fda-for-cannabidiol-for-the-treatment-of-neonatal-hypoxic-ischemic-encephalopathy https://wxpress.wuxiapptec.com/detail/494/sancilio-company-inc-granted-orphan-drug-designation-by-fda-for-its-docosahexaenoic-acid-for-the-treatment-of-sickle-cell-disease https://wxpress.wuxiapptec.com/detail/495/bio-path-holdings-granted-orphan-drug-designation-for-liposomal-grb-2-in-acute-myeloid-leukemia https://wxpress.wuxiapptec.com/detail/496/kythera-biopharmaceuticals-announces-fda-approval-of-kybella-first-and-only-submental-contouring-injectable-drug https://wxpress.wuxiapptec.com/detail/497/pfizer-s-rapamune-sirolimus-becomes-first-fda-approved-treatment-for-lymphangioleiomyomatosis-lam-a-rare-progressive-lung-disease https://wxpress.wuxiapptec.com/detail/498/incyte-s-hodgkin-lymphoma-treatment-receives-fda-orphan-drug-designation https://wxpress.wuxiapptec.com/detail/499/fda-grants-revlimid-orphan-drug-designation-for-the-treatment-of-extranodal-marginal-zone-lymphoma-of-mucosa-associated-lymphoid-tissue https://wxpress.wuxiapptec.com/detail/500/vernalis-and-tris-pharma-receive-fda-approval-of-nda-for-tuzistra-xr https://wxpress.wuxiapptec.com/detail/501/golden-biotechnology-antroquinonol-granted-orphan-drug-designation-by-fda-for-treatment-of-acute-myeloid-leukemia https://wxpress.wuxiapptec.com/detail/502/cialis-by-eli-lilly-receives-orphan-drug-designation-from-fda-for-the-treatment-of-duchenne-muscular-dystrophy https://wxpress.wuxiapptec.com/detail/503/retrophin-receives-fda-orphan-drug-designation-for-re-024-for-the-treatment-of-pantothenate-kinase-associated-neurodegeneration https://wxpress.wuxiapptec.com/detail/504/us-fda-grants-breakthrough-therapy-designation-for-investigational-bcl-2-inhibitor-venetoclax-in-17p-deletion-relapsed-refractory-chronic-lymphocytic-leukemia https://wxpress.wuxiapptec.com/detail/505/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-gastric-cancer https://wxpress.wuxiapptec.com/detail/506/fda-grants-edaravone-orphan-drug-designation-for-treatment-of-amyotrophic-lateral-sclerosis https://wxpress.wuxiapptec.com/detail/507/bms-receives-orphan-drug-designation-from-fda-for-investigational-antibody-anti-etau-for-treatment-of-progressive-supranuclear-palsy https://wxpress.wuxiapptec.com/detail/508/infacort-receives-orphan-drug-designation-from-fda-for-treatment-of-pediatric-adrenal-insufficiency https://wxpress.wuxiapptec.com/detail/509/fda-grants-orphan-drug-designation-to-glycomimetics-gmi-1271-for-treatment-of-acute-myleogenous-leukemia-aml- https://wxpress.wuxiapptec.com/detail/510/fda-approves-treximet-for-use-in-pediatric-patients https://wxpress.wuxiapptec.com/detail/511/abbvie-receives-orphan-drug-designation-for-humira-from-fda-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa https://wxpress.wuxiapptec.com/detail/512/u-s-fda-approves-invega-trinza-first-and-only-four-times-a-year-treatment-for-schizophrenia https://wxpress.wuxiapptec.com/detail/513/bristol-myers-squibb-receives-amended-u-s-fda-breakthrough-therapy-designation-for-investigational-daclatasvir-based-hepatitis-c-regimen https://wxpress.wuxiapptec.com/detail/514/alnylam-receives-orphan-drug-designation-from-us-fda-for-revusiran-an-investigational-rnai-therapeutic-for-the-treatment-of-transthyretin-ttr-mediated-amyloidosis-attr-amyloidosis- https://wxpress.wuxiapptec.com/detail/515/fda-approves-boehringer-ingelheim-s-stiolto-respimat-for-once-daily-maintenance-treatment-of-airflow-obstruction-in-patients-with-chronic-obstructive-pulmonary-disease https://wxpress.wuxiapptec.com/detail/516/cerulean-pharma-receives-orphan-drug-designation-from-fda-for-its-crlx101-for-the-treatment-of-ovarian-cancer https://wxpress.wuxiapptec.com/detail/517/massachusetts-upstart-scpharmaceuticals-rakes-in-45-6-million-series-b https://wxpress.wuxiapptec.com/detail/518/listen-up-researchers-versant-ventures-to-fund-2-dozen-biotech-startups-with-400-million https://wxpress.wuxiapptec.com/detail/519/chinese-upstart-ascletis-bags-100-million-in-series-b-financing https://wxpress.wuxiapptec.com/detail/520/novel-anti-il-6-antibody-for-rheumatoid-arthritis-from-wuxi-medimmune-azn-joint-venture-receives-clinical-trial-permit-ctp-from-cfda https://wxpress.wuxiapptec.com/detail/521/wuxi-apptec-acquires-biology-focused-r-d-service-leader-hd-biosciences https://wxpress.wuxiapptec.com/detail/522/adarza-biosystems-bags-17-million-series-c https://wxpress.wuxiapptec.com/detail/523/wuxi-launches-representative-office-in-israel-forms-strategic-collaboration-with-pontifax https://wxpress.wuxiapptec.com/detail/524/wuxi-launches-an-online-resource-and-service-platform-dedicated-to-rare-diseases https://wxpress.wuxiapptec.com/detail/525/hutchison-china-meditech-chi-med-release-biopharma-initiates-a-phase-ii-study-of-sulfatinib-in-second-line-biliary-tract-cancer-in-china https://wxpress.wuxiapptec.com/detail/526/fda-allows-marketing-of-first-whole-slide-imaging-system-for-digital-pathology https://wxpress.wuxiapptec.com/detail/527/industry-experts-discuss-challenges-and-opportunities-in-rare-disease-r-d https://wxpress.wuxiapptec.com/detail/528/study-points-toward-diagnostic-test-for-parkinson-s https://wxpress.wuxiapptec.com/detail/529/u-s-fda-granted-lilly-s-effient-orphan-drug-designation-for-treatment-of-sickle-cell-disease https://wxpress.wuxiapptec.com/detail/530/atlas-genetics-raises-35m-in-series-d-fundraising https://wxpress.wuxiapptec.com/detail/531/cue-biopharma-debuts-with-26-million-in-invested-capital-to-develop-next-generation-biologics-to-selectively-control-t-cell-activity https://wxpress.wuxiapptec.com/detail/532/actavis-receives-fda-approval-for-viberzi-eluxadoline-for-the-treatment-of-irritable-bowel-syndrome-with-diarrhea-ibs-d-in-adults https://wxpress.wuxiapptec.com/detail/533/on-target-unc-researcher-arms-platelets-to-deliver-cancer-immunotherapy https://wxpress.wuxiapptec.com/detail/534/existing-medications-for-erectile-dysfunction-may-alleviate-symptoms-of-duchene-muscular-dystrophy https://wxpress.wuxiapptec.com/detail/535/salix-announces-fda-approval-of-xifaxan-for-the-treatment-of-ibs-d-irritable-bowel-syndrome-with-diarrhea- https://wxpress.wuxiapptec.com/detail/536/china-turns-to-precision-medicine-in-fight-against-cancer https://wxpress.wuxiapptec.com/detail/537/u-s-fda-approves-humalog-200-units-ml-kwikpen- https://wxpress.wuxiapptec.com/detail/538/wuxi-wins-prestigious-scrip-award-for-best-company-in-the-emerging-market https://wxpress.wuxiapptec.com/detail/539/wuxi-presents-2014-life-science-and-chemistry-awards https://wxpress.wuxiapptec.com/detail/540/wuxi-opening-offices-in-boston-and-san-francisco https://wxpress.wuxiapptec.com/detail/541/aptose-biosciences-granted-orphan-drug-designation-by-u-s-fda-for-apto-253-in-acute-myeloid-leukemia https://wxpress.wuxiapptec.com/detail/542/apitope-receives-orphan-designation-in-the-european-union-for-atx-f8-117-for-the-treatment-of-haemophilia-a https://wxpress.wuxiapptec.com/detail/543/medicinova-announces-fda-granted-orphan-drug-designation-to-mn-166-ibudilast-for-krabbe-disease https://wxpress.wuxiapptec.com/detail/544/fda-grants-breakthrough-therapy-designation-for-genzyme-s-olipudase-alfa https://wxpress.wuxiapptec.com/detail/545/2014-wuxi-year-in-review https://wxpress.wuxiapptec.com/detail/546/fda-grants-breakthrough-therapy-designation-for-actemra-tocilizumab-in-systemic-sclerosis https://wxpress.wuxiapptec.com/detail/547/agios-pharmaceuticals-announces-fda-orphan-drug-designation-granted-to-ag-120-for-treatment-of-idh1-mutant-positive-acute-myelogenous-leukemia https://wxpress.wuxiapptec.com/detail/548/wuxi-launches-mobile-app-to-enable-chemistry-on-the-go https://wxpress.wuxiapptec.com/detail/549/fda-approves-gazyva-obinutuzumab-for-people-with-previously-untreated-chronic-lymphocytic-leukemia-cll- https://wxpress.wuxiapptec.com/detail/550/seres-therapeutics-receives-fda-breakthrough-therapy-designation-for-its-lead-product-candidate-ser-109 https://wxpress.wuxiapptec.com/detail/551/3rd-annual-wuxi-global-forum-at-jp-morgan-healthcare-conference-a-great-success https://wxpress.wuxiapptec.com/detail/552/corbus-pharmaceuticals-announces-fda-orphan-drug-designation-for-resunab-tm-for-the-treatment-of-systemic-sclerosis-scleroderma- https://wxpress.wuxiapptec.com/detail/553/fda-approves-second-brain-implant-for-parkinson-s-symptoms https://wxpress.wuxiapptec.com/detail/554/u-s-fda-ganted-rgx-104-two-orphan-drug-designations-for-the-treatment-of-ovarian-cancer-and-glioblastoma-multiforme https://wxpress.wuxiapptec.com/detail/555/antibodies-designed-to-combat-ebola-may-provide-protection-from-the-rare-but-deadly-infection https://wxpress.wuxiapptec.com/detail/556/edwards-receives-fda-approval-for-sapien-3-transcatheter-heart-valve https://wxpress.wuxiapptec.com/detail/557/first-crystal-structure-of-human-glut1-solved https://wxpress.wuxiapptec.com/detail/558/keytruda-receives-orphan-drug-designation-from-the-u-s-fda-for-the-treatment-of-gastric-cancer https://wxpress.wuxiapptec.com/detail/559/aimmune-therapeutics-receives-fda-breakthrough-therapy-designation-for-ar101 https://wxpress.wuxiapptec.com/detail/560/fda-approved-natpara-the-first-biologic-to-treat-a-rare-disease-hypoparathyroidism https://wxpress.wuxiapptec.com/detail/561/non-surgical-prescription-vision-aid-cleared-by-fda-for-use-by-people-who-are-profoundly-blind https://wxpress.wuxiapptec.com/detail/562/wuxi-throws-a-grand-annual-party https://wxpress.wuxiapptec.com/detail/563/the-medicines-company-announces-fda-approval-of-kengreal-cangrelor-as-an-adjunct-to-percutaneous-coronary-intervention-pci-for-reducing-thrombotic-events https://wxpress.wuxiapptec.com/detail/564/webinar-developing-a-more-efficient-mab-discovery-process https://wxpress.wuxiapptec.com/detail/565/medtronic-announces-fda-approval-for-new-tavr-system-introduces-first-and-only-recapturable-heart-valve-in-u-s- https://wxpress.wuxiapptec.com/detail/566/rgx-104-received-another-orphan-drug-designation-from-u-s-fda-for-treatment-of-malignant-melanoma-stages-iib-to-iv https://wxpress.wuxiapptec.com/detail/567/fda-approves-orkambi-lumacaftor-ivacaftor-the-first-medicine-to-treat-the-underlying-cause-of-cystic-fibrosis-for-people-ages-12-and-older-with-two-copies-of-the-f508del-mutation https://wxpress.wuxiapptec.com/detail/568/cyclica-ceo-naheed-kurji-says-ai-could-create-a-new-paradigm-for-drug-development https://wxpress.wuxiapptec.com/detail/569/wuxi-s-sta-wins-cmo-leadership-award https://wxpress.wuxiapptec.com/detail/570/bcx4161-a-promising-new-orally-administered-drug-for-the-rare-and-genetic-disorder-hereditary-angioedema-received-fast-track-status-from-the-fda https://wxpress.wuxiapptec.com/detail/571/dr-ge-li-recognized-as-the-25-most-influential-people-in-biopharma-in-2015- https://wxpress.wuxiapptec.com/detail/572/wuxi-v-lab-app-releases-version-2-0-with-new-interface-and-payment-feature https://wxpress.wuxiapptec.com/detail/573/fda-granted-breakthrough-status-to-intercept-s-drug-obeticholic-acid-oca-for-nonalcoholic-steatohepatitis-nash-with-liver-fibrosis https://wxpress.wuxiapptec.com/detail/574/a-new-weapon-to-fight-breast-cancer https://wxpress.wuxiapptec.com/detail/575/wuxi-launches-e-commerce-platform-for-chemistry-products https://wxpress.wuxiapptec.com/detail/576/gene-therapy-offers-potentially-new-treatment-for-beta-thalassemia-patients https://wxpress.wuxiapptec.com/detail/577/wuxipra-appoints-two-key-executives https://wxpress.wuxiapptec.com/detail/578/wuxi-joins-consortium-to-acquire-ambrx https://wxpress.wuxiapptec.com/detail/579/an-interview-with-dr-rick-panicucci-vice-president-of-pharmaceutical-development-services https://wxpress.wuxiapptec.com/detail/580/regenxbio-and-wuxi-collaborate-on-gene-therapy-manufacturing https://wxpress.wuxiapptec.com/detail/581/wuxi-collaborates-with-university-of-pennsylvania-to-produce-gene-therapies https://wxpress.wuxiapptec.com/detail/582/wuxi-s-bio-2015-recap https://wxpress.wuxiapptec.com/detail/583/ois-n-biotechnologies-seeks-a-path-to-fountain-of-youth- https://wxpress.wuxiapptec.com/detail/584/wuxi-sponsors-iati-biomed-conference-in-tel-aviv-may-12-14 https://wxpress.wuxiapptec.com/detail/585/how-to-develop-products-in-china-and-asia-panel-discussion-at-upcoming-bio-international-convention https://wxpress.wuxiapptec.com/detail/587/what-s-next-in-neuroscience-r-d-panel-discussion-at-upcoming-bio-international-convention https://wxpress.wuxiapptec.com/detail/588/global-scale-the-secret-behind-mayo-clinic-s-strategy-in-improving-patient-care-in-china-and-across-the-map https://wxpress.wuxiapptec.com/detail/589/sage-therapeutics-on-fast-track-towards-cns-cures https://wxpress.wuxiapptec.com/detail/590/tagrisso-azd9291-approved-by-u-s-fda-for-patients-with-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer https://wxpress.wuxiapptec.com/detail/591/arch-biopartners-receives-orphan-drug-designation-for-fda-for-ab569-for-treatment-of-pseudomonas-aeruginosa-pulmonary-infections-in-patients-with-cystic-fibrosis https://wxpress.wuxiapptec.com/detail/592/darzalex-approved-by-u-s-fda-first-human-anti-cd38-monoclonal-antibody-available-for-the-treatment-of-multiple-myeloma https://wxpress.wuxiapptec.com/detail/593/rejuvenation-the-role-of-plasma-proteins-in-counterbalancing-aging https://wxpress.wuxiapptec.com/detail/594/triphase-accelerator-announces-fda-orphan-drug-designation-for-marizomib-in-malignant-glioma https://wxpress.wuxiapptec.com/detail/596/takeda-gets-fda-approval-for-multiple-myeloma-pill-developed-in-cambridge https://wxpress.wuxiapptec.com/detail/597/a-new-hope-for-glioblastoma https://wxpress.wuxiapptec.com/detail/598/meet-idsu-leadership-an-interview-with-tao-guo-vp-of-medicinal-chemistry https://wxpress.wuxiapptec.com/detail/599/fda-approves-lenvima-for-treatment-of-progressive-radioiodine-refractory-differentiated-thyroid-cancer-rr-dtc- https://wxpress.wuxiapptec.com/detail/600/fda-approves-bristol-myers-squibb-s-opdivo-to-treat-advanced-form-of-kidney-cancer https://wxpress.wuxiapptec.com/detail/601/fda-approves-lilly-s-portrazza-to-treat-advanced-squamous-non-small-cell-lung-cancer https://wxpress.wuxiapptec.com/detail/602/genentech-s-new-combination-chemotherapy-prolonged-breast-cancer-patient-lives-for-extra-16-months https://wxpress.wuxiapptec.com/detail/603/combatting-the-hep-b-virus-an-interview-with-george-hartman-novira-therapeutics https://wxpress.wuxiapptec.com/detail/604/harvard-s-david-sinclair-treats-aging-as-a-disease-and-plans-to-launch-a-clinical-trial-to-prove-it https://wxpress.wuxiapptec.com/detail/605/wuxi-cambridge-office-grand-opening https://wxpress.wuxiapptec.com/detail/606/the-first-true-anti-aging-drug- https://wxpress.wuxiapptec.com/detail/607/dr-ge-li-receives-executive-of-the-year-award-from-scrip https://wxpress.wuxiapptec.com/detail/608/advances-in-targeted-therapies-against-lung-cancer https://wxpress.wuxiapptec.com/detail/609/alexion-gets-fda-drug-approval-kanuma https://wxpress.wuxiapptec.com/detail/610/fda-grants-roche-s-alecensa-alectinib-approval-for-people-with-a-specific-type-of-lung-cancer https://wxpress.wuxiapptec.com/detail/611/wuxi-healthcare-ventures-ii-closes-with-oversubscription https://wxpress.wuxiapptec.com/detail/612/fda-grants-fast-track-designation-for-medicinova-s-mn-166-ibudilast-for-the-treatment-of-amyotrophic-lateral-sclerosis https://wxpress.wuxiapptec.com/detail/613/wuxi-and-medimmune-form-a-strategic-alliance-to-develop-innovative-biologics-in-china-for-astrazeneca https://wxpress.wuxiapptec.com/detail/614/actelion-gets-u-s-fda-approval-for-new-pah-drug-uptravi-to-complement-tracleer https://wxpress.wuxiapptec.com/detail/615/astrazeneca-s-zurampic-lesinurad-approved-by-u-s-fda-for-patients-with-gout https://wxpress.wuxiapptec.com/detail/616/ionis-pharmaceuticals-receives-orphan-drug-designation-from-the-us-fda-for-ionis-htt-rx-for-the-treatment-of-patients-with-huntington-s-disease https://wxpress.wuxiapptec.com/detail/617/vtesse-inc-announces-fda-s-granting-of-breakthrough-therapy-designation-for-vts-270-in-niemann-pick-type-c1-disease https://wxpress.wuxiapptec.com/detail/618/chinabio-partnering-forum-2015 https://wxpress.wuxiapptec.com/detail/619/wuxi-plans-120-million-investment-in-new-integrated-biologics-solution-center-to-expedite-biologics-development-from-ideas-to-clinic https://wxpress.wuxiapptec.com/detail/620/congratulations-to-hua-medicine-on-filing-ind-in-us-for-its-novel-gka-based-diabetes-drug https://wxpress.wuxiapptec.com/detail/621/congratulations-to-chia-tai-tianqing-pharmaceutical-group-and-janssen-for-licensing-agreement https://wxpress.wuxiapptec.com/detail/622/wuxi-to-build-new-cell-therapy-manufacturing-facility-for-car-t-cells-and-other-cancer-immunotherapies https://wxpress.wuxiapptec.com/detail/623/impax-receives-approval-of-emverm-mebendazole-chewable-tablets https://wxpress.wuxiapptec.com/detail/624/wuxi-s-dr-steve-yang-to-moderate-biologics-china-s-new-wave-of-innovation- https://wxpress.wuxiapptec.com/detail/625/cholbam-cholic-acid-now-approved-in-the-u-s-for-patients-with-bile-acid-synthesis-disorders https://wxpress.wuxiapptec.com/detail/626/fda-granted-orphan-drug-designation-for-cmd-003 https://wxpress.wuxiapptec.com/detail/627/masitinib-receives-orphan-drug-designation-for-amyotrophic-lateral-sclerosis-from-fda https://wxpress.wuxiapptec.com/detail/628/novartis-receives-two-new-fda-approvals-for-cosentyx-to-treat-patients-with-ankylosing-spondylitis-and-psoriatic-arthritis-in-the-us https://wxpress.wuxiapptec.com/detail/629/neurometrix-reports-regulatory-approval-for-dpncheck-in-china https://wxpress.wuxiapptec.com/detail/630/nicox-receives-orphan-drug-designation-from-fda-for-naproxcinod-in-duchenne-muscular-dystrophy https://wxpress.wuxiapptec.com/detail/631/fda-approves-new-kyprolis-carfilzomib-combination-therapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma https://wxpress.wuxiapptec.com/detail/632/u-s-fda-approves-botox-for-the-treatment-of-lower-limb-spasticity-in-adults https://wxpress.wuxiapptec.com/detail/633/wuxi-healthcare-ventures-joins-financing-rounds-for-twist-bioscience-and-syros-pharmaceuticals https://wxpress.wuxiapptec.com/detail/635/tracon-announces-fda-orphan-drug-designation-for-trc105-in-soft-tissue-sarcoma https://wxpress.wuxiapptec.com/detail/636/dako-an-agilent-technologies-company-announces-expanded-fda-approval-of-complementary-diagnostic-test-to-include-melanoma https://wxpress.wuxiapptec.com/detail/637/sta-at-informex-2016 https://wxpress.wuxiapptec.com/detail/638/dilaforette-receives-orphan-drug-designation-in-the-u-s-for-sevuparin-in-sickle-cell-disease https://wxpress.wuxiapptec.com/detail/639/over-1-100-executives-signed-up-for-4th-annual-wuxi-global-forum-at-j-p-morgan-conference https://wxpress.wuxiapptec.com/detail/640/fda-approves-merck-s-new-hep-c-pill https://wxpress.wuxiapptec.com/detail/641/wuxi-congratulates-msd-on-receiving-fda-approval-of-zepatier- https://wxpress.wuxiapptec.com/detail/642/asterias-biotherapeutics-receives-orphan-drug-designation-for-ast-opc1-for-the-treatment-of-acute-spinal-cord-injury https://wxpress.wuxiapptec.com/detail/643/u-s-fda-approves-expanded-use-of-bristol-myers-squibb-s-daklinza-daclatasvir-for-additional-challenging-to-treat-patients-with-genotype-1-or-genotype-3-chronic-hepatitis-c https://wxpress.wuxiapptec.com/detail/644/immunomedics-breast-cancer-drug-gets-breakthrough-therapy-designation-from-u-s-fda https://wxpress.wuxiapptec.com/detail/645/epizyme-s-tazemetostat-granted-orphan-drug-designation-for-malignant-rhabdoid-tumors-by-u-s-fda https://wxpress.wuxiapptec.com/detail/646/cidara-receives-orphan-drug-designation-for-novel-echinocandin-cd101-iv-in-candidemia-and-invasive-candidiasis https://wxpress.wuxiapptec.com/detail/647/amarantus-receives-orphan-drug-designation-from-the-us-fda-for-eltoprazine-in-the-treatment-of-parkinson-s-disease-levodopa-induced-dyskinesia https://wxpress.wuxiapptec.com/detail/648/onl-therapeutics-receives-orphan-drug-designation-for-onl1204-for-treatment-of-retinal-detachment-from-fda https://wxpress.wuxiapptec.com/detail/649/mina-developing-unique-rna-pathway-to-help-patient-s-own-cells-fight-disease https://wxpress.wuxiapptec.com/detail/650/the-future-of-cancer-therapy-an-interview-with-yinon-ben-neriah-hebrew-university https://wxpress.wuxiapptec.com/detail/651/fda-approves-two-supplemental-indications-for-harvoni-in-chronic-hepatitis-c-patients-with-advanced-liver-disease https://wxpress.wuxiapptec.com/detail/652/tarix-orphan-granted-orphan-drug-status-for-txa127-as-potential-treatment-for-congenital-muscular-dystrophy https://wxpress.wuxiapptec.com/detail/653/durvalumab-granted-breakthrough-therapy-designation-by-us-fda-for-treatment-of-patients-with-pd-l1-positive-urothelial-bladder-cancer https://wxpress.wuxiapptec.com/detail/654/fda-grants-breakthrough-therapy-designation-for-genentech-s-investigational-medicine-ocrelizumab-in-primary-progressive-multiple-sclerosis https://wxpress.wuxiapptec.com/detail/655/sirnaomics-counts-on-new-rna-technology-to-fuel-wide-ranging-cancer-fibrosis-pipeline https://wxpress.wuxiapptec.com/detail/656/wuxi-releases-new-mobile-app-for-compound-sourcing https://wxpress.wuxiapptec.com/detail/657/u-s-fda-approves-ucb-s-new-epilepsy-treatment-briviact-for-patients-with-partial-onset-seizures https://wxpress.wuxiapptec.com/detail/658/new-rna-technology-boosting-gritstone-s-immuno-therapeutics-program-in-fight-against-cancer https://wxpress.wuxiapptec.com/detail/659/how-cool-science-translates-into-successful-companies-a-chat-with-unity-biotechnology-ceo-nathaniel-david https://wxpress.wuxiapptec.com/detail/660/in-cancer-boosting-chemotherapy-while-reducing-toxic-side-effects-is-a-potential-breakthrough https://wxpress.wuxiapptec.com/detail/661/prima-biomed-and-wuxi-biologics-announce-first-dose-of-chinese-manufactured-biologics-in-eu-clinical-trial https://wxpress.wuxiapptec.com/detail/662/wuxi-s-sta-subsidiary-opens-new-campus-in-changzhou https://wxpress.wuxiapptec.com/detail/663/webinar-pioneering-approaches-to-dismantling-cancer https://wxpress.wuxiapptec.com/detail/664/wuxi-spring-reception-in-san-francisco https://wxpress.wuxiapptec.com/detail/665/a-breakthrough-gene-therapy-aims-to-subdue-brain-cancer https://wxpress.wuxiapptec.com/detail/666/wuxi-apptec-s-enabling-capability-recognized-by-partners-and-philadelphia-authority-at-bio-2019 https://wxpress.wuxiapptec.com/detail/667/at-the-cutting-edge-of-r-d-enablement-the-virtual-korean-biotech-bridge-biotherapeutics-builds-a-pipeline-of-first-and-best-in-class-therapeutics https://wxpress.wuxiapptec.com/detail/668/enabling-synthetic-and-medicinal-chemists-with-the-predictive-power-of-quantum-mechanics https://wxpress.wuxiapptec.com/detail/669/a-conversation-with-richard-lerner-delopen-promotes-worldwide-academic-research-using-dna-encoded-libraries-far-more-than-just-a-numbers-game https://wxpress.wuxiapptec.com/detail/670/wuxi-apptec-lab-testing-division-s-bioanalytical-service-unit-passed-fda-inspection https://wxpress.wuxiapptec.com/detail/671/wuxi-biologics-receives-asia-pacific-best-bioprocessing-excellence-award-from-imapac https://wxpress.wuxiapptec.com/detail/672/novimmune-s-ni-0501-granted-breakthrough-therapy-designation-by-us-fda-for-treatment-of-patients-with-primary-hemophagocytic-lymphohistiocytosis-hlh- https://wxpress.wuxiapptec.com/detail/673/u-s-fda-approves-new-psoriasis-drug-taltz-from-eli-lilly https://wxpress.wuxiapptec.com/detail/674/labnetwork-integrates-with-reaxys-to-offer-seamless-experience-from-chemistry-research-to-purchase https://wxpress.wuxiapptec.com/detail/675/wuxi-opens-office-in-south-korea https://wxpress.wuxiapptec.com/detail/676/wuxi-biologics-congratulates-ambrx-and-zmc-for-successful-dosing-of-a-novel-antibody-drug-conjugate-in-australia https://wxpress.wuxiapptec.com/detail/677/u-s-fda-approves-descovy-gilead-s-third-taf-based-hiv-therapy https://wxpress.wuxiapptec.com/detail/678/fda-approves-world-s-smallest-pacemaker-for-u-s-patients https://wxpress.wuxiapptec.com/detail/679/juno-therapeutics-and-wuxi-start-new-company-to-develop-novel-cell-based-cancer-immunotherapies-in-china https://wxpress.wuxiapptec.com/detail/680/global-wuxi-webinar-pioneering-approaches-to-dismantling-cancer https://wxpress.wuxiapptec.com/detail/681/wuxi-lab-testing-division-s-analytical-and-stability-testing-facilities-passed-fda-inspection https://wxpress.wuxiapptec.com/detail/682/fda-grants-priority-review-for-roche-s-cancer-immunotherapy-atezolizumab-in-specific-type-of-lung-cancer https://wxpress.wuxiapptec.com/detail/683/abbvie-receives-fda-accelerated-approval-of-venclexta-for-a-rare-type-of-leukemia https://wxpress.wuxiapptec.com/detail/684/epigenomics-receives-fda-approval-for-epi-procolon- https://wxpress.wuxiapptec.com/detail/685/wuxi-acquires-crelux https://wxpress.wuxiapptec.com/detail/686/fda-approves-gilotrif-as-new-oral-treatment-option-for-patients-with-squamous-cell-carcinoma-of-the-lung https://wxpress.wuxiapptec.com/detail/687/placing-early-bets-in-biotech https://wxpress.wuxiapptec.com/detail/688/labnetwork-forges-ecommerce-alliances-with-leading-chemical-providers https://wxpress.wuxiapptec.com/detail/689/webinar-tackling-the-1-drug-product-development-problem-solubility https://wxpress.wuxiapptec.com/detail/690/novartis-receives-three-fda-breakthrough-therapy-designations-for-ilaris-to-treat-rare-types-of-periodic-fever-syndromes https://wxpress.wuxiapptec.com/detail/691/wuxi-at-iati-biomed-conference-in-tel-aviv-may-24-26-2016 https://wxpress.wuxiapptec.com/detail/692/therabron-therapeutics-receives-fda-fast-track-designation-for-rhcc10-for-the-prevention-of-chronic-lung-disease-related-to-premature-birth https://wxpress.wuxiapptec.com/detail/693/fda-approves-acadia-pharmaceuticals-nuplazid-pimavanserin-the-first-drug-approved-for-the-treatment-of-hallucinations-and-delusions-associated-with-parkinson-s-disease-psychosis https://wxpress.wuxiapptec.com/detail/694/fda-grants-priority-review-for-amgen-s-supplemental-biologics-license-application-for-blincyto-blinatumomab- https://wxpress.wuxiapptec.com/detail/695/wuxi-healthcare-ventures-appoints-renowned-life-science-entrepreneur-gregory-verdine-as-newest-venture-partner https://wxpress.wuxiapptec.com/detail/696/building-a-global-bridge-for-life-science-innovation https://wxpress.wuxiapptec.com/detail/697/next-generation-immuno-oncology-creating-a-new-pathway-to-eat-cancer-a-chat-with-jonathan-macquitty-ceo-forty-seven https://wxpress.wuxiapptec.com/detail/698/fda-grants-priority-review-for-lilly-s-olaratumab-an-investigational-medicine-for-advanced-soft-tissue-sarcoma https://wxpress.wuxiapptec.com/detail/699/wuxi-biologics-congratulates-tesaro-for-anti-tim-3-antibody-ind-submission-in-the-u-s- https://wxpress.wuxiapptec.com/detail/700/wuxi-s-pharmaceutical-development-service-and-analytical-service-passes-ema-inspection https://wxpress.wuxiapptec.com/detail/701/astrazeneca-s-selumetinib-granted-orphan-status-for-adjuvant-treatment-of-differentiated-thyroid-cancer https://wxpress.wuxiapptec.com/detail/702/fda-approves-eisai-s-lenvima-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-in-combination-with-everolimus-following-prior-anti-angiogenic-therapy https://wxpress.wuxiapptec.com/detail/703/fda-grants-soligenix-fast-track-designation-for-sgx943-for-the-treatment-of-melioidosis https://wxpress.wuxiapptec.com/detail/704/fda-approves-new-diagnostic-imaging-agent-to-detect-rare-neuroendocrine-tumors https://wxpress.wuxiapptec.com/detail/705/fda-approves-first-blood-test-to-detect-gene-mutation-associated-with-non-small-cell-lung-cancer https://wxpress.wuxiapptec.com/detail/706/it-s-in-the-genes-the-quest-to-develop-a-cure-for-rare-genetic-diseases https://wxpress.wuxiapptec.com/detail/707/a-golden-age-of-drug-discovery-in-cancer https://wxpress.wuxiapptec.com/detail/708/shire-receives-fda-breakthrough-therapy-designation-for-shp621-and-shp625-investigational-products-for-rare-gastrointestinal-conditions https://wxpress.wuxiapptec.com/detail/709/espero-pharmaceuticals-receives-fda-approval-for-gonitro-sublingual-powder https://wxpress.wuxiapptec.com/detail/710/wuxi-s-bio-2016-recap https://wxpress.wuxiapptec.com/detail/711/fda-grants-breakthrough-therapy-designation-for-incyte-s-ruxolitinib-jakafi-in-acute-graft-versus-host-disease https://wxpress.wuxiapptec.com/detail/712/aslan-receives-orphan-drug-designation-for-varlitinib-in-gastric-cancer https://wxpress.wuxiapptec.com/detail/713/fda-approves-gilead-s-epclusa-sofosbuvir-velpatasvir-for-the-treatment-of-all-genotypes-of-chronic-hepatitis-c https://wxpress.wuxiapptec.com/detail/715/genfit-seeking-breakthrough-therapies-for-little-known-but-severe-liver-diseases-to-make-a-real-difference-in-patients-lives https://wxpress.wuxiapptec.com/detail/716/wuxi-apptec-named-one-of-mit-technology-review-s-50-smartest-companies https://wxpress.wuxiapptec.com/detail/717/mei-s-oncology-programs-aim-new-drug-development-at-specific-genetic-targets-with-breakthrough-potential https://wxpress.wuxiapptec.com/detail/718/oncolytics-developing-new-drug-to-energize-the-immune-system-to-fight-defiant-pancreatic-cancer https://wxpress.wuxiapptec.com/detail/719/wuxi-sta-shanghai-changzhou-facilities-pass-u-s-fda-inspections https://wxpress.wuxiapptec.com/detail/720/rna-focused-drug-development-emerging-as-a-dominant-treatment-modality https://wxpress.wuxiapptec.com/detail/721/bellicum-is-designing-a-double-barrel-next-generation-car-t-therapy-to-take-on-pancreatic-cancer https://wxpress.wuxiapptec.com/detail/722/towards-the-realization-of-a-dream-ending-the-rare-disease-neurofibromatosa-a-conversation-with-the-children-s-tumor-foundation-s-president-annette-bakker-ph-d- https://wxpress.wuxiapptec.com/detail/723/expanding-the-target-universe-and-the-therapeutic-opportunities-of-small-molecules-through-covalency-previously-thought-impossible https://wxpress.wuxiapptec.com/detail/724/the-peculiarity-of-cancer-metastasis-may-be-the-key-to-controlling-the-disease https://wxpress.wuxiapptec.com/detail/725/wuxi-apptec-reports-first-half-2019-interim-results https://wxpress.wuxiapptec.com/detail/726/inivata-seeking-to-develop-liquid-biopsy-tests-to-detect-deadly-lung-cancers-at-a-more-treatable-stage https://wxpress.wuxiapptec.com/detail/727/ose-immunotherapeutics-developing-tedopi-to-jump-start-cytotoxic-t-cell-response-in-lung-cancer-fight https://wxpress.wuxiapptec.com/detail/728/the-quest-for-anti-fibrotic-therapies-leads-to-blade-therapeutics https://wxpress.wuxiapptec.com/detail/729/leading-the-charge-in-the-fight-against-cancer-laurie-glimcher-m-d-president-and-ceo-dana-farber-cancer-institute https://wxpress.wuxiapptec.com/detail/730/pioneering-gut-science-kintai-therapeutics-is-bringing-a-new-small-molecule-modality-to-fruition https://wxpress.wuxiapptec.com/detail/731/kymera-s-next-generation-therapeutics-protein-degraders-new-way-and-new-rules-for-a-new-modality https://wxpress.wuxiapptec.com/detail/732/redefining-therapeutics-through-control-of-gene-expression-a-conversation-with-nancy-simonian-m-d-president-and-ceo-syros-pharmaceuticals https://wxpress.wuxiapptec.com/detail/733/oncternal-therapeutics-pursuing-novel-treatment-for-ewing-sarcoma-in-challenging-field-of-pediatric-cancer https://wxpress.wuxiapptec.com/detail/734/blaze-bioscience-shines-a-light-on-tumor-cells-to-guide-pediatric-brain-cancer-surgeons https://wxpress.wuxiapptec.com/detail/735/finch-therapeutics-taps-into-the-human-microbiome-to-find-disease-causes-and-cures https://wxpress.wuxiapptec.com/detail/736/halozyme-utilizing-unique-tumor-microenvironment-pathway-to-fight-pancreatic-cancer https://wxpress.wuxiapptec.com/detail/737/wuxi-apptec-research-service-division-and-biosolveit-introduce-galaxi-a-vast-new-chemical-space-of-tangible-molecules https://wxpress.wuxiapptec.com/detail/738/paving-the-way-to-a-new-generation-of-cns-drugs-karuna-ceo-steve-paul-neuroscience-s-renaissance-physician-psychiatrist-neuroscientist-and-executive https://wxpress.wuxiapptec.com/detail/739/delmar-developing-drug-to-cross-the-blood-brain-barrier-to-treat-deadly-glioblastoma-disease https://wxpress.wuxiapptec.com/detail/740/salarius-believes-children-should-not-be-left-behind-in-the-fight-against-cancer https://wxpress.wuxiapptec.com/detail/741/oncoceutics-hopes-to-develop-the-first-effective-drug-for-high-grade-glioma-by-blocking-dopamine-from-feeding-the-deadly-cancer-s-growth https://wxpress.wuxiapptec.com/detail/742/wuxi-sta-s-jinshan-facility-passes-ema-inspection https://wxpress.wuxiapptec.com/detail/743/foghorn-therapeutics-gene-traffic-control-product-platform-regulating-gene-expression-to-fight-intractable-disease https://wxpress.wuxiapptec.com/detail/744/wuxi-apptec-reports-third-quarter-2019-results https://wxpress.wuxiapptec.com/detail/745/capricor-therapeutics-seeking-new-cell-therapy-for-deadly-duchenne-disease https://wxpress.wuxiapptec.com/detail/746/wuxi-apptec-opens-new-medical-device-testing-center-in-suzhou https://wxpress.wuxiapptec.com/detail/747/divide-conquer-seeks-to-disrupt-cell-communication-in-new-therapeutic-approach-to-glioblastoma https://wxpress.wuxiapptec.com/detail/748/oncosenx-developing-new-gene-therapy-approach-that-kills-cancer-cells-by-suicide- https://wxpress.wuxiapptec.com/detail/749/the-prostate-cancer-foundation-a-tireless-worker-and-voice-in-the-development-for-better-treatments https://wxpress.wuxiapptec.com/detail/750/avalon-venture-s-jay-lichter-discusses-coi-community-of-innovation-a-different-way-for-drug-discovery-and-development https://wxpress.wuxiapptec.com/detail/751/dr-ge-li-awarded-ceo-of-the-year-at-cphi-worldwide-2019 https://wxpress.wuxiapptec.com/detail/752/wuxi-apptec-receives-2019-global-integrated-drug-development-competitive-strategy-innovation-leadership-award-from-frost-sullivan https://wxpress.wuxiapptec.com/detail/753/wuxi-apptec-s-lab-testing-division-expands-toxicology-facility-in-suzhou-china https://wxpress.wuxiapptec.com/detail/754/sqz-biotech-s-unique-technology-squeezes-cells-to-transform-them-into-therapeutics https://wxpress.wuxiapptec.com/detail/755/wuxi-atu-and-genemedicine-sign-development-and-manufacturing-agreement-for-oncolytic-virus-products https://wxpress.wuxiapptec.com/detail/756/rapt-therapeutics-sees-charged-lung-cancer-tumors-as-inviting-targets-for-lead-drug-flx475 https://wxpress.wuxiapptec.com/detail/757/refuge-biotechnologies-developing-smart-cells-to-fight-cancer-inside-the-human-body https://wxpress.wuxiapptec.com/detail/758/sotio-arms-dendritic-cells-for-immunotherapy-against-cancer https://wxpress.wuxiapptec.com/detail/759/tdi-serves-as-a-bridge-between-academia-and-industry-leveraging-all-it-needs-for-innovation https://wxpress.wuxiapptec.com/detail/760/wuxi-sta-opens-oligonucleotide-large-scale-manufacturing-facility https://wxpress.wuxiapptec.com/detail/762/wuxi-advanced-therapies-launches-new-world-class-aav-vector-suspension-platform https://wxpress.wuxiapptec.com/detail/763/wuxi-apptec-china-sites-resume-operations-after-extended-lunar-new-year-holiday https://wxpress.wuxiapptec.com/detail/764/wuxi-apptec-wuhan-site-resumes-operation https://wxpress.wuxiapptec.com/detail/765/apitope-s-research-seeks-to-put-cause-of-multiple-sclerosis-into-remission https://wxpress.wuxiapptec.com/detail/766/wuxi-apptec-reports-strong-2019-annual-results https://wxpress.wuxiapptec.com/detail/767/harvard-s-francisco-quintana-explores-the-impact-of-environmental-factors-on-the-pathogenesis-of-multiple-sclerosis https://wxpress.wuxiapptec.com/detail/768/tackling-covid-19-at-a-potential-achilles-heel-si-rna-a-conversation-with-alnylam-s-ceo-john-maraganore https://wxpress.wuxiapptec.com/detail/769/urgently-responding-to-this-outbreak-vigilantly-preparing-for-the-next https://wxpress.wuxiapptec.com/detail/770/aridis-trying-to-improve-infection-control-for-cystic-fibrosis-patients-with-alternative-to-antibiotics https://wxpress.wuxiapptec.com/detail/771/biotechnology-innovation-organization-s-bio-s-covid-19-lead-george-scangos-the-call-to-action https://wxpress.wuxiapptec.com/detail/772/biocom-s-president-and-ceo-joe-panetta-fostering-global-collaboration-covid-19-takeaways https://wxpress.wuxiapptec.com/detail/773/wuxi-apptec-reports-solid-first-quarter-2020-results https://wxpress.wuxiapptec.com/detail/774/turning-the-tides-on-neurodegeneration-the-denali-way-a-conversation-with-ryan-watts-ceo- https://wxpress.wuxiapptec.com/detail/775/stronger-together-steve-bates-ceo-uk-bioindustry-association-encourages-a-fundamental-rethink https://wxpress.wuxiapptec.com/detail/776/geneuro-believes-its-new-and-unique-pathway-in-ms-research-can-lead-to-a-truly-effective-treatment https://wxpress.wuxiapptec.com/detail/777/wuxi-advanced-therapies-launches-new-closed-process-car-t-cell-therapy-platform https://wxpress.wuxiapptec.com/detail/778/vaccinex-s-cancer-research-may-lead-to-effective-treatment-for-deadly-huntington-s-disease https://wxpress.wuxiapptec.com/detail/779/click-is-pioneering-and-developing-cutting-edge-digital-therapeutics-to-transform-medicine https://wxpress.wuxiapptec.com/detail/780/powerhouse-collaborator-massbio-s-president-ceo-bob-coughlin-optimistically-embraces-industry-changes https://wxpress.wuxiapptec.com/detail/781/disease-modifying-rna-therapies-from-recode-therapeutics-target-rare-lung-diseases https://wxpress.wuxiapptec.com/detail/782/practical-considerations-for-bringing-drug-candidates-to-phase-1-clinical-trail https://wxpress.wuxiapptec.com/detail/783/wuxi-apptec-appoints-dr-david-chang-as-ceo-of-wuxi-advanced-therapies-business-unit https://wxpress.wuxiapptec.com/detail/784/bia-mhra-regulatory-innovation-conference-2020 https://wxpress.wuxiapptec.com/detail/785/tg-therapeutics-early-oncology-research-leading-to-new-ms-therapeutic https://wxpress.wuxiapptec.com/detail/786/wuxi-apptec-collaborating-against-covid-19 https://wxpress.wuxiapptec.com/detail/787/wuxi-apptec-achieved-strong-growth-in-first-half-of-2020-with-china-sites-resuming-full-operations https://wxpress.wuxiapptec.com/detail/788/one-stop-cell-and-gene-therapy-solutions-for-global-innovators-a-conversation-with-david-chang-ceo-of-wuxi-atu https://wxpress.wuxiapptec.com/detail/789/big-ideas-yield-transformative-results-for-sma-patients-a-conversation-with-stuart-peltz-the-founder-and-ceo-of-ptc-therapeutics https://wxpress.wuxiapptec.com/detail/790/galera-therapeutics-reducing-toxicity-increasing-anti-cancer-efficacy-for-patients https://wxpress.wuxiapptec.com/detail/791/cydan-sets-the-pace-for-rare-disease-r-d https://wxpress.wuxiapptec.com/detail/792/wuxi-apptec-reports-strong-third-quarter-2020-results https://wxpress.wuxiapptec.com/detail/793/wuxi-advanced-therapies-expands-philadelphia-campus-with-new-state-of-the-art-testing-laboratory https://wxpress.wuxiapptec.com/detail/794/vigeneron-and-wuxi-advanced-therapies-enter-strategic-manufacturing-partnership-for-next-generation-ophthalmic-gene-therapy https://wxpress.wuxiapptec.com/detail/795/wuxi-sta-to-purchase-bristol-myers-squibb-manufacturing-facility-in-couvet-switzerland https://wxpress.wuxiapptec.com/detail/796/wuxi-apptec-reports-strong-2020-annual-results https://wxpress.wuxiapptec.com/detail/797/next-act-europe-china-collaborations-during-west-east-roundtable https://wxpress.wuxiapptec.com/detail/798/wuxi-sta-chooses-middletown-delaware-for-new-pharmaceutical-manufacturing-campus https://wxpress.wuxiapptec.com/detail/799/wuxi-sta-completes-acquisition-of-bristol-myers-squibb-manufacturing-facility-in-couvet-switzerland https://wxpress.wuxiapptec.com/detail/800/wuxi-apptec-reports-strong-2021-interim-results https://wxpress.wuxiapptec.com/detail/801/wuxi-apptec-receives-aa-esg-rating-from-msci https://wxpress.wuxiapptec.com/detail/802/wuxi-atu-opens-new-facility-in-philadelphia-tripling-testing-capacity-to-support-global-customers https://wxpress.wuxiapptec.com/detail/803/wuxi-apptec-receives-2021-global-customer-value-leadership-award-from-frost-sullivan https://wxpress.wuxiapptec.com/detail/804/delivering-on-the-promise-of-new-modalities-an-interview-with-sue-dillon-ceo-of-aro-biotherapeutics https://wxpress.wuxiapptec.com/detail/805/delivering-on-the-promise-of-new-modalities-an-interview-with-david-main-president-ceo-notch-therapeutics https://wxpress.wuxiapptec.com/detail/806/life-sciences-night-at-the-opera-2022 https://wxpress.wuxiapptec.com/detail/807/delivering-on-the-promise-of-new-modalities-an-interview-with-ray-tabibiazar-m-d-ceo-chairman-of-saliogen-therapeutics https://wxpress.wuxiapptec.com/detail/808/wuxi-apptec-recognized-as-top-rated-esg-company-by-sustainalytics https://wxpress.wuxiapptec.com/detail/809/wuxi-apptec-unites-with-san-diego-life-sciences-community-to-support-local-art https://wxpress.wuxiapptec.com/detail/810/wuxi-sta-s-couvet-site-honors-world-recycling-day https://wxpress.wuxiapptec.com/detail/811/delivering-on-the-promise-of-new-modalities-an-interview-with-kunwoo-lee-ph-d-ceo-of-genedit https://wxpress.wuxiapptec.com/detail/812/delivering-on-the-promise-of-new-modalities-an-interview-with-amber-van-laar-vp-clinical-development-of-askbio https://wxpress.wuxiapptec.com/detail/813/wuxi-atu-wugen-announce-manufacturing-partnership-to-expedite-the-delivery-of-novel-cell-cancer-immunotherapies https://wxpress.wuxiapptec.com/detail/814/wuxi-apptec-plans-to-build-a-new-site-in-singapore-better-serving-global-partners-and-advancing-healthcare-innovation https://wxpress.wuxiapptec.com/detail/815/delivering-on-the-promise-of-new-modalities-an-interview-with-daniel-getts-ceo-co-founder-board-director-of-myeloid-therapeutics https://wxpress.wuxiapptec.com/detail/816/delivering-on-the-promise-of-new-modalities-an-interview-with-james-mcarthur-president-ceo-of-pepgen https://wxpress.wuxiapptec.com/detail/817/wuxi-apptec-reports-record-first-half-results-in-2022 https://wxpress.wuxiapptec.com/detail/818/a-futuristic-biopharma-company-addressing-some-of-the-world-s-biggest-health-problems https://wxpress.wuxiapptec.com/detail/819/wuxi-apptec-appoints-edward-hu-as-co-ceo https://wxpress.wuxiapptec.com/detail/821/ecosystem-builder-accelerating-the-translation-of-promising-university-research-for-human-health https://wxpress.wuxiapptec.com/detail/822/biotech-trade-associations-play-integral-role-in-building-global-bioeconomies- https://wxpress.wuxiapptec.com/detail/823/role-model-merging-academic-science-with-industry-to-accelerate-drug-discovery https://wxpress.wuxiapptec.com/detail/826/cancer-prevention-pharmaceuticals-follows-small-molecule-pathway-to-find-new-therapy-for-rare-disease https://wxpress.wuxiapptec.com/detail/827/small-molecule-chemotherapy-may-play-a-big-role-in-cancer-immunotherapy https://wxpress.wuxiapptec.com/detail/828/the-synthesis-of-an-entrepreneur-merging-a-passion-for-biochemistry-synthetic-chemistry-and-bioactive-molecules-in-academia https://wxpress.wuxiapptec.com/detail/829/schr-dinger-and-wuxi-apptec-announce-the-launch-of-faxian-therapeutics-to-enable-accelerated-drug-discovery https://wxpress.wuxiapptec.com/detail/830/delivering-on-the-promise-of-new-modalities-an-interview-with-karen-kozarsky-co-founder-chief-scientific-officer-swanbio-therapeutics https://wxpress.wuxiapptec.com/detail/831/delivering-on-the-promise-of-new-modalities-an-interview-with-mark-frohlich-ceo-indapta-therapeutics https://wxpress.wuxiapptec.com/detail/833/delivering-on-the-promise-of-new-therapies-for-rare-diseases-an-interview-with-ralph-laufer-cso-of-lysogene https://wxpress.wuxiapptec.com/detail/834/delivering-on-the-promise-of-new-modalities-an-interview-with-elvire-gouze-ceo-founder-innoskel-sas-france https://wxpress.wuxiapptec.com/detail/835/delivering-on-the-promise-of-new-modalities-an-interview-with-andrea-van-elsas-cso-abata-therapeutics-venture-partner-third-rock-ventures https://wxpress.wuxiapptec.com/detail/836/delivering-on-the-promise-of-new-modalities-an-interview-with-george-wu-co-founder-ceo-amberstone-biosciences https://wxpress.wuxiapptec.com/detail/837/delivering-on-the-promise-of-new-modalities-an-interview-with-yann-chong-tan-founder-ceo-nuevocor https://wxpress.wuxiapptec.com/detail/838/delivering-on-the-promise-of-new-therapies-for-rare-diseases-an-interview-with-david-walker-director-of-chemistry-sentinel-oncology https://wxpress.wuxiapptec.com/detail/839/wuxi-atu-announces-licensing-agreement-with-janssen-for-tessa-technology https://wxpress.wuxiapptec.com/detail/840/protein-degradation-shifting-the-paradigm-of-resistance-and-undruggables-for-unmet-medical-needs-in-cancer-neuroscience-and-beyond https://wxpress.wuxiapptec.com/detail/841/pathway-to-patients-moving-impactful-science-from-the-lab-to-the-bedside https://wxpress.wuxiapptec.com/detail/842/wuxi-sta-breaks-ground-for-new-pharmaceutical-manufacturing-facility-in-middletown-delaware https://wxpress.wuxiapptec.com/detail/843/wuxi-sta-opens-a-new-sterile-lipid-nanoparticle-formulation-facility-to-enhance-global-crdmo-services-for-customers https://wxpress.wuxiapptec.com/detail/844/delivering-on-the-promise-of-new-therapies-for-rare-diseases-an-interview-with-xinyu-zhao-professor-waisman-center-and-department-of-neuroscience-university-of-wisconsin-madison https://wxpress.wuxiapptec.com/detail/845/delivering-on-the-promise-of-new-therapies-for-rare-diseases-an-interview-with-lili-mao-director-of-clinical-development-unit-and-head-of-project-management-office-at-gexval https://wxpress.wuxiapptec.com/detail/846/delivering-on-the-promise-of-new-modalities-an-interview-with-nikole-kimes-ceo-co-founder-siolta-therapeutics https://wxpress.wuxiapptec.com/detail/847/delivering-on-the-promise-of-new-modalities-an-interview-with-zachary-hornby-president-ceo-boundless-bio https://wxpress.wuxiapptec.com/detail/848/live-now-join-global-leaders-for-dialogues-on-healthy-aging- https://wxpress.wuxiapptec.com/detail/849/delivering-on-the-promise-of-new-modalities-wuxi-apptec-interview-series https://wxpress.wuxiapptec.com/detail/850/delivering-on-the-promise-of-new-modalities-an-interview-with-geoff-hamilton-co-founder-ceo-stemson-therapeutics https://wxpress.wuxiapptec.com/detail/851/china-electronics-data-and-wuxi-apptec-form-cw-data-a-joint-venture-to-offer-one-stop-healthcare-big-data-solutions https://wxpress.wuxiapptec.com/detail/852/wuxi-apptec-provides-easy-access-to-80-billion-dna-encoded-small-molecules-libraries https://wxpress.wuxiapptec.com/detail/853/wuxi-apptec-group-and-mayo-clinic-receive-2018-medtech-insight-award-for-best-alliance https://wxpress.wuxiapptec.com/detail/854/historic-approvals-highlighted-at-the-second-china-innovative-drug-ecosystem-forum-2018 https://wxpress.wuxiapptec.com/detail/855/new-therapies-targeting-causes-of-parkinson-s-disease-generate-optimism-for-a-cure https://wxpress.wuxiapptec.com/detail/868/wuxi-global-forum-2023 https://wxpress.wuxiapptec.com/detail/881/delivering-on-the-promise-of-new-modalities-an-interview-with-maria-luisa-pineda-ceo-and-co-founder-envisagenics https://wxpress.wuxiapptec.com/detail/882/delivering-on-the-promise-of-new-modalities-an-interview-with-sj-lee-ceo-orum-therapeutics https://wxpress.wuxiapptec.com/detail/883/digital-wuxi-global-forum-2023 https://wxpress.wuxiapptec.com/detail/889/delivering-on-the-promise-of-new-modalities-an-interview-with-christopher-thanos-president-ceo-co-founder-actym-therapeutics https://wxpress.wuxiapptec.com/detail/890/wuxi-apptec-named-to-the-2022-dow-jones-sustainability-world-index https://wxpress.wuxiapptec.com/detail/892/wuxi-apptec-named-industry-mover-in-s-p-global-sustainability-yearbook-2023 https://wxpress.wuxiapptec.com/detail/896/wuxi-apptec-reports-record-results-in-2022 https://wxpress.wuxiapptec.com/detail/897/wuxi-innovation-day-2023 https://wxpress.wuxiapptec.com/detail/898/bold-innovation-that-matters-episode-ii https://wxpress.wuxiapptec.com/detail/899/mental-health-r-d-a-global-priority https://wxpress.wuxiapptec.com/detail/901/wuxi-apptec-continued-solid-growth-in-first-quarter-of-2023-on-top-of-an-exceptionally-strong-year-of-2022- https://wxpress.wuxiapptec.com/detail/902/digital-wuxi-innovation-day-innovation-that-matters https://wxpress.wuxiapptec.com/detail/903/wuxi-innovation-day-on-march-20-2023-in-basel https://wxpress.wuxiapptec.com/detail/906/digital-wuxi-global-forum-2023 https://wxpress.wuxiapptec.com/detail/907/bold-innovation-that-matters-episode-2 https://wxpress.wuxiapptec.com/detail/908/wuxi-innovation-day-in-basel https://wxpress.wuxiapptec.com/detail/909/bold-innovation-that-matters-episode-3 https://wxpress.wuxiapptec.com/detail/910/delivering-on-the-promise-of-new-modalities-an-interview-with-reagan-jarvis-co-founder-ceo-anocca-ab https://wxpress.wuxiapptec.com/detail/911/delivering-on-the-promise-of-new-therapies-for-rare-diseases-an-interview-with-adrian-newman-tancredi-ceo-of-neurolixis https://wxpress.wuxiapptec.com/detail/912/the-journey-to-druggable- https://wxpress.wuxiapptec.com/detail/913/wuxi-innovation-day-reception-in-boston https://wxpress.wuxiapptec.com/detail/914/harnessing-our-collective-power-wuxi-online-forum-ii-on-covid-19 https://wxpress.wuxiapptec.com/detail/915/wuxi-apptec-announced-strong-results-of-the-second-quarter-and-first-half-of-2023-on-top-of-an-exceptionally-strong-year-in-2022- https://wxpress.wuxiapptec.com/detail/916/bia-techbio-uk-conference https://wxpress.wuxiapptec.com/detail/917/bold-innovation-that-matters-episode-4 https://wxpress.wuxiapptec.com/detail/918/wuxi-apptec-continued-solid-growth-in-the-first-three-quarters-of-2023-on-top-of-an-exceptionally-strong-year-in-2022-with-profit-growth-continuously-exceeding-revenue-growth https://wxpress.wuxiapptec.com/detail/919/wuxi-apptec-named-2023-global-contract-research-development-and-manufacturing-organization-company-of-the-year-by-frost-sullivan https://wxpress.wuxiapptec.com/detail/920/wuxi-global-forum-2024 https://wxpress.wuxiapptec.com/detail/921/digital-wuxi-global-forum-2024 https://wxpress.wuxiapptec.com/detail/922/wuxi-apptec-triples-peptide-manufacturing-capacity-and-launches-the-new-taixing-api-manufacturing-site https://wxpress.wuxiapptec.com/detail/923/wuxi-advanced-therapies-receives-fda-approval-to-manufacture-iovance-s-amtagvi-lifileucel-for-advanced-melanoma https://wxpress.wuxiapptec.com/detail/924/bold-innovation-that-matters-episode-5 https://wxpress.wuxiapptec.com/detail/925/wuxi-apptec-revenue-surpassed-rmb40-billion-in-2023-and-adjusted-non-ifrs-net-profit-exceeded-rmb10-billion-for-the-first-time https://wxpress.wuxiapptec.com/detail/926/wuxi-apptec-achieved-first-quarter-2024-target-despite-external-challenges-maintaining-stable-operations https://wxpress.wuxiapptec.com/detail/927/wuxi-global-forum-2025 https://wxpress.wuxiapptec.com/detail/928/how-research-education-can-impact-an-aging-society-a-singapore-perspective https://wxpress.wuxiapptec.com/detail/929/abstracts-of-noteworthy-academic-papers-by-asia-pacific-scholars https://wxpress.wuxiapptec.com/detail/930/takeda-s-3-billion-deals-highlight-asia-pacific-pharma-activity https://wxpress.wuxiapptec.com/detail/931/new-modality-goes-mainstream-62-promising-cns-drug-pipelines-in-asia https://wxpress.wuxiapptec.com/detail/932/world-lung-cancer-day-celebrating-breakthroughs-in-lung-cancer-treatment https://wxpress.wuxiapptec.com/detail/937/despite-external-challenges-wuxi-apptec-maintained-stable-operations-in-first-half-of-2024 https://wxpress.wuxiapptec.com/detail/938/nordic-innovation-in-focus-a-conversation-with-jessica-martinsson-ceo-of-swedenbio https://wxpress.wuxiapptec.com/detail/939/the-non-linear-path-of-aging-a-conversation-with-professor-michael-snyder-on-biomolecular-shifts-and-health https://wxpress.wuxiapptec.com/detail/940/tackling-fibrosis-and-cancer-a-conversation-with-john-hood-co-founder-and-chief-executive-officer-of-endeavor-biomedicines https://wxpress.wuxiapptec.com/detail/941/seizing-the-moment-a-global-call-to-action-against-alzheimer-s-with-george-vradenburg https://wxpress.wuxiapptec.com/detail/942/changing-the-game-of-parkinson-s-disease-an-interview-with-howard-federoff-cmo-of-kenai-therapeutics https://wxpress.wuxiapptec.com/detail/943/world-heart-day-celebrating-breakthroughs-in-hypertension-treatment-and-innovating-for-every-heartbeat https://wxpress.wuxiapptec.com/detail/944/marking-world-alzheimer-s-day-celebrating-decades-of-innovation https://wxpress.wuxiapptec.com/detail/945/-test-nordic-innovation-in-focus-a-conversation-with-jessica-martinsson-ceo-of-swedenbio https://wxpress.wuxiapptec.com/detail/946/wuxi-apptec-named-to-the-ftse4good-index-series-for-the-second-consecutive-year https://wxpress.wuxiapptec.com/detail/947/wuxi-apptec-maintains-aa-msci-esg-rating-for-the-fourth-consecutive-year https://wxpress.wuxiapptec.com/detail/948/wuxi-apptec-joins-the-battle-against-melanoma-at-philadelphia-s-5k-run https://wxpress.wuxiapptec.com/detail/949/wuxi-day https://wxpress.wuxiapptec.com/detail/950/innovation-that-matters-the-latest-from-wxpress https://wxpress.wuxiapptec.com/detail/951/innovation-that-matters-the-latest-from-wxpress-september-edition https://wxpress.wuxiapptec.com/detail/952/bold-innovation-that-matters-episode-2-preview-only- https://wxpress.wuxiapptec.com/detail/953/bold-innovation-that-matters-episode-3-preview-only- https://wxpress.wuxiapptec.com/detail/954/bold-innovation-that-matters-episode-4-preview-only- https://wxpress.wuxiapptec.com/detail/963/despite-external-challenges-wuxi-apptec-revenue-and-profit-continued-to-grow-qoq-in-the-first-three-quarters-of-2024 https://wxpress.wuxiapptec.com/detail/964/wuxi-apptec-named-global-crdmo-company-of-the-year-by-frost-sullivan-for-the-eighth-consecutive-year https://wxpress.wuxiapptec.com/detail/965/wuxi-apptec-ranked-1-in-global-life-sciences-tools-services-industry-in-2024-s-p-global-corporate-sustainability-assessment https://wxpress.wuxiapptec.com/detail/966/wuxi-apptec-s-couvet-site-receives-ecovadis-2024-silver-medal-rating https://wxpress.wuxiapptec.com/detail/967/investing-in-a-sustainable-future-for-antibiotics-a-conversation-with-dr-henry-skinner-ceo-of-amr-action-fund https://wxpress.wuxiapptec.com/detail/968/technology-at-the-forefront-in-tackling-antimicrobial-resistance-a-conversation-with-dr-jim-collins-termeer-professor-of-medical-engineering-and-science-at-mit https://wxpress.wuxiapptec.com/detail/969/combating-the-silent-pandemic-a-conversation-with-dr-michael-lobritz-global-head-infectious-diseases-therapeutic-area-roche-pharma-research-early-development https://wxpress.wuxiapptec.com/detail/970/2024-a-pivotal-year-for-amr-global-action-a-conversation-with-dr-tim-jinks-head-of-infectious-disease-interventions-at-wellcome https://wxpress.wuxiapptec.com/detail/971/strengthening-early-stage-amr-innovation-a-conversation-with-dr-erin-duffy-chief-of-research-development-at-carb-x https://wxpress.wuxiapptec.com/detail/972/marking-word-diabetes-day-a-tribute-to-the-breakthrough-therapies-that-transform-diabetes-care https://wxpress.wuxiapptec.com/detail/973/innovating-for-impact-the-evolving-landscape-of-amr-therapeutics https://wxpress.wuxiapptec.com/detail/974/exclusive-kol-insights-from-wellcome-roche-mit-carb-x-amr-action-fund-wxpress-november-edition https://wxpress.wuxiapptec.com/detail/975/wuxi-apptec-receives-gold-medal-in-2024-ecovadis-sustainability-rating https://wxpress.wuxiapptec.com/detail/976/faqs-on-hosting-an-executive-roundtable-wuxi-global-forum-2025 https://wxpress.wuxiapptec.com/detail/977/wuxi-apptec-s-commitment-to-sustainability-recognized-by-the-dow-jones-sustainability-indices-djsi-for-the-fourth-consecutive-year https://wxpress.wuxiapptec.com/detail/978/wuxi-apptec-joins-the-pharmaceutical-supply-chain-initiative-psci- https://wxpress.wuxiapptec.com/detail/979/opening-plenary-state-of-innovation https://wxpress.wuxiapptec.com/detail/980/experience-the-energy-wuxi-global-forum-recap https://wxpress.wuxiapptec.com/detail/981/welcome-to-the-digital-wuxi-global-forum-2025 https://wxpress.wuxiapptec.com/detail/982/digital-wuxi-global-forum-2025 https://wxpress.wuxiapptec.com/detail/983/charting-the-future-of-cancer-care-insights-from-dr-laurie-glimcher-president-and-ceo-emerita-of-dana-farber-cancer-institute- https://wxpress.wuxiapptec.com/detail/984/double-the-hope-a-conversation-with-annette-bakker-ceo-the-children-s-tumor-foundation https://wxpress.wuxiapptec.com/detail/985/-let-us-not-forget-the-most-vulnerable-a-conversation-with-prof-christoph-klein-professor-and-chair-dr-von-hauner-children-s-hospital-at-ludwig-maximilians-university https://wxpress.wuxiapptec.com/detail/986/bending-the-curve-of-drug-discovery-and-patient-care-a-conversation-with-paulo-fontoura-chief-medical-officer-of-xaira-therapeutics https://wxpress.wuxiapptec.com/detail/987/nano-rare-mega-impact-a-conversation-with-stanley-t-crooke-founder-ceo-and-chairman-of-the-board-n-lorem-foundation https://wxpress.wuxiapptec.com/detail/988/a-global-village-for-global-impact-a-conversation-with-michael-altorfer-ceo-of-the-swiss-biotech-association https://wxpress.wuxiapptec.com/detail/989/from-ice-buckets-to-breakthroughs-a-conversation-with-calaneet-balas-president-and-ceo-of-the-als-association https://wxpress.wuxiapptec.com/detail/990/exclusive-kol-insights-from-dana-farber-xaira-swiss-biotech-association-and-rare-diseases-thought-leaders-wxpress-march-edition https://wxpress.wuxiapptec.com/detail/991/wuxi-apptec-revenue-and-profit-achieved-steady-qoq-growth-in-2024-meeting-full-year-guidance-q4-revenue-and-profit-both-reached-record-highs https://wxpress.wuxiapptec.com/detail/992/wuxi-night-milan-a-celebration-of-global-partnerships https://wxpress.wuxiapptec.com/detail/993/wuxi-apptec-s-changzhou-and-taixing-api-sites-successfully-pass-fda-inspections https://wxpress.wuxiapptec.com/detail/994/wuxi-apptec-q1-2025-revenue-profit-resume-double-digit-growth-revenue-up-21-0-yoy-adjusted-non-ifrs-net-profit-up-40-0-yoy-backlog-for-continuing-operations-up-47-1-yoy https://wxpress.wuxiapptec.com/detail/995/safeguarding-clean-waters-wuxi-apptec-singapore-team-takes-action https://wxpress.wuxiapptec.com/detail/996/at-the-heart-of-europe-wuxi-apptec-munich-team-underscores-health-commitment https://wxpress.wuxiapptec.com/detail/997/at-the-cradle-of-breakthrough-medicines-wuxi-apptec-boston-team-champions-community-responsibility https://wxpress.wuxiapptec.com/detail/998/rooted-in-the-innovation-coast-wuxi-apptec-san-diego-team-gives-back-to-its-ecosystem https://wxpress.wuxiapptec.com/detail/999/at-the-medicine-chest-of-the-world-wuxi-apptec-new-jersey-team-evolves-together-with-local-community https://wxpress.wuxiapptec.com/detail/1000/it-takes-a-global-village-wuxi-executive-breakfast-in-basel https://wxpress.wuxiapptec.com/detail/1001/charting-new-paths-in-oncology-insights-from-dr-alberto-toso-chief-scientific-officer-of-alentis-therapeutics https://wxpress.wuxiapptec.com/detail/1002/championing-early-stage-biotech-investment-in-europe-insights-from-dr-karen-wagner-managing-partner-of-ysios-capital https://wxpress.wuxiapptec.com/detail/1003/beyond-the-age-of-alchemy-insights-from-dr-eva-maria-hempe-head-of-healthcare-life-sciences-emea-of-nvidia https://wxpress.wuxiapptec.com/detail/1004/cystic-fibrosis-shining-a-light-on-progress-through-partnership https://wxpress.wuxiapptec.com/detail/1005/advancing-melanoma-therapies-through-innovation https://wxpress.wuxiapptec.com/detail/1006/crdmo-accelerating-next-generation-oral-cyclic-peptide-from-lead-optimization-to-gmp-readiness https://wxpress.wuxiapptec.com/detail/1007/strengthening-munich-s-biotech-momentum-a-conversation-between-dr-ralf-huss-and-dr-karl-naegler https://wxpress.wuxiapptec.com/detail/1008/turbocharging-the-skunkworks-of-academia-a-conversation-with-dr-donald-ingber-founding-director-of-the-wyss-institute-at-harvard https://wxpress.wuxiapptec.com/detail/1009/advancing-the-new-era-of-neuroscience-a-conversation-with-dr-azad-bonni-svp-and-global-head-of-neuroscience-rare-diseases-roche-pharma-research-early-development https://wxpress.wuxiapptec.com/detail/1010/renewed-optimism-on-alzheimer-s-disease-a-conversation-with-dr-howard-fillit-co-founder-and-chief-science-officer-alzheimer-s-drug-discovery-foundation https://wxpress.wuxiapptec.com/detail/1011/the-right-time-for-translating-innovation-in-cns-therapeutics-a-conversation-with-dr-shane-hegarty-co-founder-and-chief-scientific-officer-of-axonis-therapeutics https://wxpress.wuxiapptec.com/detail/1012/turbocharging-translation-perspectives-from-roche-addf-axonis-harvard-biom-and-sofinnova-wxpress-june-edition https://wxpress.wuxiapptec.com/detail/1013/wuxi-apptec-earns-sbti-validation-for-near-term-emissions-reduction-targets https://wxpress.wuxiapptec.com/detail/1014/farewell-to-a-legend-remembering-dr-atul-butte https://wxpress.wuxiapptec.com/detail/1015/wuxi-apptec-nantong-site-receives-2025-architizer-a-award-for-its-unique-blend-of-technology-and-humanity https://wxpress.wuxiapptec.com/detail/1016/wuxi-apptec-receives-msci-esg-aaa-leader-rating https://wxpress.wuxiapptec.com/detail/1017/model-region-munich-with-companies-like-wuxi-apptec-munich-is-becoming-europe-s-leading-biotech-hub https://wxpress.wuxiapptec.com/detail/1018/scaling-success-how-wuxi-apptec-aims-to-catalyze-europe-s-biotech-transformation https://wxpress.wuxiapptec.com/detail/1019/anzeige-modellregion-m-nchen-mit-unternehmen-wie-wuxi-apptec-wird-m-nchen-zum-f-hrenden-biotech-standort-in-europa https://wxpress.wuxiapptec.com/detail/1020/crdmo-from-concept-to-ind-how-wuxi-apptec-supports-targeted-protein-degraders-development-in-12-months https://wxpress.wuxiapptec.com/detail/1021/crdmo-targeting-the-undruggable-how-wuxi-apptec-is-advancing-protac-translation https://wxpress.wuxiapptec.com/detail/1025/wuxi-apptec-achieves-strong-growth-in-revenue-and-profit-for-q2-and-h1-2025-h1-revenue-from-continuing-operations-up-24-2-yoy-and-adjusted-non-ifrs-net-profit-up-44-4-yoy https://wxpress.wuxiapptec.com/detail/1026/wuxi-apptec-named-constituent-of-the-ftse4good-index-series-for-third-consecutive-year https://wxpress.wuxiapptec.com/detail/1027/h1-2025-fda-novel-drug-approvals-review-first-in-class-therapies-make-up-half-of-all-approvals https://wxpress.wuxiapptec.com/detail/1028/h1-2025-update-on-conjugated-therapeutics https://wxpress.wuxiapptec.com/detail/1029/crdmo-h1-2025-review-of-targeted-protein-degraders- https://wxpress.wuxiapptec.com/detail/1030/turning-the-tide-against-ovarian-cancer https://wxpress.wuxiapptec.com/detail/1031/partnering-for-progress-driving-the-future-of-brain-tumor-therapies https://wxpress.wuxiapptec.com/detail/1032/accelerating-hope-powering-innovation-for-kidney-cancer-and-beyond https://wxpress.wuxiapptec.com/detail/1033/next-gen-delivery-of-oligonucleotide-therapeutics-game-changing-technologies https://wxpress.wuxiapptec.com/detail/1034/crdmo-targeting-the-undruggable-how-wuxi-apptec-is-advancing-protac-translation https://wxpress.wuxiapptec.com/detail/1035/breaking-through-key-bottlenecks-in-protac-development https://wxpress.wuxiapptec.com/detail/1036/crdmo-overcoming-the-efficacy-challenge-how-wuxi-apptec-supports-antisense-oligonucleotides-development-for-neurodegenerative-diseases https://wxpress.wuxiapptec.com/detail/1037/q-a-wuxi-apptec-s-key-investment-focus-is-on-expanding-capabilities-for-new-modalities https://wxpress.wuxiapptec.com/detail/1038/wuxi-apptec-awarded-gold-medal-by-ecovadis-sustainability-rating-for-second-consecutive-year https://wxpress.wuxiapptec.com/detail/1045/-test-wuxi-night-during-bio-europe-2025-in-vienna https://wxpress.wuxiapptec.com/detail/1046/wuxi-night-during-bio-europe-2025-in-vienna https://wxpress.wuxiapptec.com/detail/1047/wuxi-apptec-executive-afternoon-tea-during-jefferies-london-life-sciences-week https://wxpress.wuxiapptec.com/detail/1050/test https://wxpress.wuxiapptec.com/detail/1051/advancing-age-related-therapies-a-conversation-with-dr-marco-boorsma-general-partner-forbion https://wxpress.wuxiapptec.com/detail/1052/aging-well-starting-with-the-heart-a-conversation-with-dr-joseph-c-wu-director-of-the-stanford-cardiovascular-institute https://wxpress.wuxiapptec.com/detail/1053/de-risking-the-brain-a-conversation-with-dr-stacie-weninger-president-of-the-f-prime-biomedical-research-initiative https://wxpress.wuxiapptec.com/detail/1054/closing-the-gap-a-conversation-with-diane-ty-managing-director-future-of-aging-milken-institute https://wxpress.wuxiapptec.com/detail/1055/wuxi-night-gothenburg-a-celebration-of-global-partnerships https://wxpress.wuxiapptec.com/detail/1056/living-longer-living-better-perspectives-from-f-prime-forbion-stanford-and-milken-institute-wxpress-october-edition https://wxpress.wuxiapptec.com/detail/1057/in-vienna-wuxi-apptec-strikes-a-new-chord-of-innovation https://wxpress.wuxiapptec.com/detail/1058/wuxi-global-forum-2026 https://wxpress.wuxiapptec.com/detail/1059/by-the-thames-we-ignite-europe-s-innovation-momentum https://wxpress.wuxiapptec.com/detail/1060/wuxi-global-forum-2026 https://wxpress.wuxiapptec.com/detail/1062/testing-email https://wxpress.wuxiapptec.com/detail/1063/wuxi-night-during-bio-europe-spring-2026-in-lisbon https://wxpress.wuxiapptec.com/detail/1064/wuxi-executive-breakfast-during-swiss-biotech-day-2026-in-basel https://wxpress.wuxiapptec.com/detail/1065/wuxi-executive-breakfast-during-swiss-biotech-day-2026-in-basel复制信息 https://wxpress.wuxiapptec.com/detail/1066/wuxi-night-in-lisbon-a-spirit-of-connection-shapes-biotech-s-next-chapter https://wxpress.wuxiapptec.com/detail/blog/2/how-wuxi-apptec-embeds-quality-a-global-blueprint-for-trust-and-excellence https://wxpress.wuxiapptec.com/detail/blog/3/wuxi-apptec-s-enduring-strength-the-crdmo-model-as-a-foundation-for-long-term-growth https://wxpress.wuxiapptec.com/detail/blog/5/wuxi-apptec-pioneering-role-in-advancing-targeted-protein-degradation https://wxpress.wuxiapptec.com/detail/blog/8/how-wuxi-apptec-s-crdmo-model-drives-business-growth https://wxpress.wuxiapptec.com/detail/blog/9/unlocking-europe-s-pharma-potential-how-wuxi-apptec-bridges-the-innovation-to-market-gap https://wxpress.wuxiapptec.com/detail/blog/10/wuxi-apptec-s-new-eu-batch-release-services-what-this-means-for-european-biotech https://wxpress.wuxiapptec.com/detail/blog/11/unpacking-the-business-logic-a-deep-dive-into-wuxi-apptec-s-value-proposition https://wxpress.wuxiapptec.com/detail/blog/12/bridging-innovation-and-commercial-success-the-strategic-value-of-integrated-crdmo-services https://wxpress.wuxiapptec.com/detail/blog/14/breaking-through-key-bottlenecks-in-protac-development https://wxpress.wuxiapptec.com/detail/blog/15/crdmo-overcoming-the-efficacy-challenge-how-wuxi-apptec-supports-antisense-oligonucleotides-development-for-neurodegenerative-diseases https://wxpress.wuxiapptec.com/detail/blog/16/crdmo-targeting-the-undruggable-how-wuxi-apptec-is-advancing-protac-translation https://wxpress.wuxiapptec.com/detail/blog/17/next-gen-delivery-of-oligonucleotide-therapeutics-game-changing-technologies https://wxpress.wuxiapptec.com/detail/blog/18/review-of-targeted-protein-degraders https://wxpress.wuxiapptec.com/detail/blog/19/anzeige-modellregion-m-nchen-mit-unternehmen-wie-wuxi-apptec-wird-m-nchen-zum-f-hrenden-biotech-standort-in-europa https://wxpress.wuxiapptec.com/detail/blog/20/model-region-munich-with-companies-like-wuxi-apptec-munich-is-becoming-europe-s-leading-biotech-hub https://wxpress.wuxiapptec.com/detail/blog/22/crdmo-from-concept-to-ind-how-wuxi-apptec-supports-targeted-protein-degraders-development-in-12-months https://wxpress.wuxiapptec.com/detail/blog/23/scaling-success-how-wuxi-apptec-aims-to-catalyze-europe-s-biotech-transformation https://wxpress.wuxiapptec.com/detail/blog/24/crdmo-accelerating-next-generation-oral-cyclic-peptide-from-lead-optimization-to-gmp-readiness https://wxpress.wuxiapptec.com/detail/blog/29/what-advantages-does-a-crdmo-model-provide-over-traditional-cdmo-cro- https://wxpress.wuxiapptec.com/detail/blog/30/wuxi-apptec-s-global-footprint-serving-partners-across-asia-europe-and-north-america https://wxpress.wuxiapptec.com/detail/blog/31/wuxi-apptec-s-presence-to-europe-building-sustainable-growth-through-local-empowerment-and-community-integration https://wxpress.wuxiapptec.com/detail/blog/32/wuxi-apptec-integrating-in-local-european-ecosystems-for-sustainable-growth https://wxpress.wuxiapptec.com/detail/blog/33/building-sustainable-growth-how-wuxi-apptec-empowers-local-ecosystems-in-europe https://wxpress.wuxiapptec.com/detail/blog/34/wuxi-apptec-unveils-modernized-logo-reflecting-continued-evolution-as-a-global-healthcare-partner https://wxpress.wuxiapptec.com/detail/blog/35/the-crdmo-model-powering-the-next-decade-of-drug-innovation https://wxpress.wuxiapptec.com/detail/blog/36/making-the-impossible-triangle-possible-at-wuxi-apptec https://wxpress.wuxiapptec.com/detail/blog/37/the-second-yes-a-cancer-drug-s-second-life https://wxpress.wuxiapptec.com/detail/blog/38/accelerating-science-through-operational-excellence-a-global-approach-to-enabling-innovation https://wxpress.wuxiapptec.com/detail/blog/39/the-end-of-the-undruggable-targeted-protein-degradation-therapies-open-new-frontiers-in-cancer-care https://wxpress.wuxiapptec.com/detail/blog/40/scaling-success-how-wuxi-apptec-aims-to-catalyze-europe-s-biotech-transformation https://wxpress.wuxiapptec.com/detail/blog/41/25-years-of-impact-how-wuxi-apptec-is-enabling-the-development-of-innovative-therapeutics https://wxpress.wuxiapptec.com/detail/blog/42/wuxi-apptec-a-partner-for-innovation https://wxpress.wuxiapptec.com/detail/blog/43/always-ready-the-speed-of-discovery https://wxpress.wuxiapptec.com/detail/blog/44/building-trust-through-integration https://wxpress.wuxiapptec.com/detail/blog/46/a-promise-fulfilled-dr-john-hood-and-the-two-decade-partnership-with-wuxi-apptec https://wxpress.wuxiapptec.com/detail/blog/47/building-systems-that-protect-patients-around-the-world https://wxpress.wuxiapptec.com/detail/blog/48/from-firefighting-to-first-time-right https://wxpress.wuxiapptec.com/detail/blog/49/building-before-the-need https://wxpress.wuxiapptec.com/detail/blog/50/bridging-the-d-to-m-transition https://wxpress.wuxiapptec.com/detail/blog/51/building-wuxi-tides-from-zero-to-one https://wxpress.wuxiapptec.com/detail/blog/52/beyond-service-how-wuxi-apptec-s-crdmo-model-fuels-global-innovation-and-investor-confidence https://wxpress.wuxiapptec.com/detail/blog/53/enabling-innovation-how-wuxi-apptec-s-crdmo-provides-certainty https://wxpress.wuxiapptec.com/detail/blog/54/wuxi-apptec-strengthens-europe-s-biotech-ecosystem-through-partnerships-and-innovation-networks https://wxpress.wuxiapptec.com/detail/blog/55/wuxi-apptec-empowering-european-biotech-growth-through-collaborative-ecosystem-building https://wxpress.wuxiapptec.com/detail/blog/56/dr-richard-connell-why-wuxi-apptec-can-continue-to-grow https://wxpress.wuxiapptec.com/detail/blog/57/building-a-tool-to-democratize-discovery https://wxpress.wuxiapptec.com/detail/blog/58/the-invisible-bridge-how-dmpk-turns-chemistry-into-cures https://wxpress.wuxiapptec.com/detail/blog/59/inside-three-stories-of-crdmo-enabling-global-collaboration https://wxpress.wuxiapptec.com/detail/blog/60/a-tribute-to-dreams-ten-x-s-looking-back-on-wuxi-apptec-in-2025 https://wxpress.wuxiapptec.com/detail/blog/61/bridging-science-across-europe-and-beyond https://wxpress.wuxiapptec.com/detail/blog/62/the-teamwork-stories-she-writes https://wxpress.wuxiapptec.com/detail/blog/63/building-wuxi-apptec-s-toxicology-business-around-trust-and-flexibility https://wxpress.wuxiapptec.com/detail/blog/64/at-couvet-speed-has-an-address https://wxpress.wuxiapptec.com/detail/blog/65/building-systems-that-protect-patients-around-the-world https://wxpress.wuxiapptec.com/detail/blog/66/giving-every-science-a-chance https://wxpress.wuxiapptec.com/detail/blog/67/riding-the-line-between-trust-and-triumph https://wxpress.wuxiapptec.com/detail/blog/68/guardians-of-drug-safety https://wxpress.wuxiapptec.com/detail/blog/69/behind-the-partnership-dr-gang-lu-and-the-vast-frontier-of-molecular-glues